

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

An acceptability and feasibility pilot of medical skin camouflage for recovery of women prisoners with self-harm scarring (COVER): the study protocol.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021891
Article Type:	Protocol
Date Submitted by the Author:	24-Jan-2018
Complete List of Authors:	<p>Mitchell, Heather; University of Manchester, Centre for Women's Mental Health; Greater Manchester Mental Health NHS Foundation Trust, Psychological Research</p> <p>Abel, Kathryn; University of Manchester, Centre for Women's Mental Health; Greater Manchester Mental Health NHS Foundation Trust, Psychological Research</p> <p>Dunlop, Brendan; University of Manchester, Centre for Women's Mental Health; Greater Manchester Mental Health NHS Foundation Trust, Psychological Research</p> <p>Walker, Tammi; University of Huddersfield, Department of Psychology</p> <p>Ranote, Sandeep; North West Boroughs Healthcare NHS Foundation Trust</p> <p>Robinson, Louise; Lancashire Care NHS Foundation Trust; University of Manchester, Centre for Women's Mental Health</p> <p>Edgar, Fiona; University of Manchester, Centre for Women's Mental Health; University of Central Lancashire, Mental Health and Criminal Justice Group</p> <p>Millington, Tracy; University of Manchester, Centre for Women's Mental Health</p> <p>Meacock, Rachel; Univ Manchester,</p> <p>Shaw, Jennifer; University of Manchester, Offender Health Research Network</p> <p>Gutridge, Kerry; University of Manchester, Centre for Women's Mental Health</p>
Keywords:	Medical skin camouflage, self-harm, scarring, women prisoners, recovery, feasibility trial

SCHOLARONE™
Manuscripts

1
2
3 **An acceptability and feasibility pilot of medical skin camouflage for recovery of women**
4 **prisoners with self-harm scarring (COVER): the study protocol.**
5

6
7 Heather Mitchell,^{1,2} Professor Kathryn Abel,^{1,2} Brendan J Dunlop,^{1,2} Dr Tammi Walker,³ Dr Sandeep
8 Ranote,⁴ Dr Louise Robinson,^{5,6} Fiona Edgar,^{1,7} Tracy Millington,¹ Rachel Meacock,⁸ Professor
9 Jenny Shaw,⁹ Dr Kerry Guttridge.¹
10
11
12

13
14 **Heather Mitchell, BA**

15
16 ¹Centre for Women's Mental Health, Division of Psychology and Mental Health, School of Health
17 Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane
18 Building, Manchester, M13 9PL and ²Greater Manchester Mental Health NHS Foundation Trust,
19 Bury New Road, Prestwich, M25 3BL, United Kingdom.
20
21 heather.mitchell@manchester.ac.uk
22
23

24
25 **Professor Kathryn Abel, PhD, MB ChB**

26
27 ¹Centre for Women's Mental Health, Division of Psychology and Mental Health, School of Health
28 Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane
29 Building, Manchester, M13 9PL and ²Greater Manchester Mental Health NHS Foundation Trust,
30 Bury New Road, Prestwich, M25 3BL, United Kingdom.
31
32 kathryn.abel@manchester.ac.uk
33
34

35
36 **Brendan J Dunlop, BSc (corresponding author)**

37
38 ¹Centre for Women's Mental Health, Division of Psychology and Mental Health, School of Health
39 Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane
40 Building, Manchester, M13 9PL and ²Greater Manchester Mental Health NHS Foundation Trust,
41 Bury New Road, Prestwich, M25 3BL, United Kingdom.
42
43 brendan.dunlop@manchester.ac.uk
44

45
46 **Dr Tammi Walker, PhD**

47
48 ³Department of Psychology, School of Human & Health Sciences, University of Huddersfield, Edith
49 Key Building, Queensgate, Huddersfield, HD1 3DH, United Kingdom.
50
51 t.walker@hud.ac.uk
52

53
54 **Dr Sandeep Ranote, MB ChB**

55
56 ⁴5 Boroughs Partnership NHS Foundation Trust, Hollins Park Hospital, Hollins Lane,
57 Winwick, Warrington, WA2 8WA, United Kingdom.
58

1
2
3 sandeep.ranote@5bp.nhs.uk
4
5

6 **Dr Louise Robinson, MB ChB**

7 ⁵Lancashire Care NHS Foundation Trust, Preston, United Kingdom and ⁶Centre for Mental Health
8 and Risk, Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology,
9 Medicine and Health, University of Manchester, Jean McFarlane Building, Manchester, M13 9PL,
10 United Kingdom.

11
12
13 louise.robinson@manchester.ac.uk
14
15

16 **Fiona Edgar**

17 ¹Centre for Women's Mental Health, Division of Psychology and Mental Health, School of Health
18 Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane
19 Building, Manchester, M13 9PL, United Kingdom and ⁷Mental Health and Criminal Justice Group,
20 University of Central Lancashire, Preston, United Kingdom .

21
22
23 FEdgar@uclan.ac.uk
24
25

26 **Tracy Millington**

27 ¹Centre for Women's Mental Health, Division of Psychology and Mental Health, School of Health
28 Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane
29 Building, Manchester, M13 9PL, United Kingdom.

30
31
32 7milliebob@gmail.com
33
34

35 **Rachel Meacock, MA**

36 ⁸Manchester Centre for Health Economics, Institute of Population Health, Division of Population
37 Health, Health Services Research and Primary Care, University of Manchester, Jean McFarlane
38 Building, Manchester, M13 9PL, United Kingdom.

39
40
41 rachel.meacock@manchester.ac.uk
42
43

44 **Professor Jenny Shaw, PhD, MB ChB**

45 ⁹Offender Health Research Network, Division of Psychology and Mental Health, School of Health
46 Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane
47 Building, Manchester, M13 9PL, United Kingdom.

48
49
50 jennifer.j.shaw@manchester.ac.uk
51
52

53 **Dr Kerry Guttridge, PhD**

¹Centre for Women's Mental Health, Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane Building, Manchester, M13 9PL, United Kingdom.

kerry.gutridge@manchester.ac.uk

Word count: 5,078

Abstract

Introduction

Self-harm in prison is a major public health concern. Less than 5% of UK prisoners are women, but they carry out more than a fifth of prison self-harm. Scars resulting from self-harm can be traumatising and stigmatising, yet there has been little focus on recovery of women prisoners with self-harm scarring. Medical skin camouflage (MSC) clinics treat individuals with disfiguring skin conditions, with evidence of improved wellbeing, self-esteem and social interactions. Only one community study has piloted the use of MSC for self-harm scarring.

Methods & Analysis

We describe an acceptability and feasibility pilot randomised controlled trial; the first to examine MSC for women prisoners who self-harm. We aim to randomise 20 women prisoners to a 6-week MSC intervention and 20 to a wait-list control (to receive the MSC after the study period). We aim to train at least 6-10 long-term prisoners with personal experience of self-harm to deliver the intervention. Pre- and post-intervention, we will pilot collection of women-centred outcomes, including quality of life, wellbeing and self-esteem. We will pilot collection of self-harm incidents during the intervention, resources used to manage/treat self-harm and follow-up of women at 12-weeks from baseline. Data on recruitment, retention and drop-out will be recorded. We aim for the acceptability of the intervention to prison staff and women prisoners to be explored in qualitative interviews and focus groups.

Ethics and dissemination

1
2
3 Informed consent will be the primary consideration; it will be made clear that participation will have
4 no effect on life in prison or eligibility for parole. Due to the nature of the study, disclosures of serious
5 self-harm may need to be reported to prison officials. We aim for findings to be disseminated via
6 events at the study prison, presentations at national/international conferences, journal publications,
7 prison governor meetings and university/NHS trust communications.
8
9
10
11

12 *Trial Registration*

13
14
15
16 The trial is registered on clinicaltrials.gov (identifier: NCT02638974).
17
18

19 *Strengths & limitations of this study*

- 20
21
22
 - Several potential benefits include improved self-confidence, wellbeing and social
23 relationships.
 - Improving wellbeing may reduce likelihood of repeated self-harm, producing significant
24 savings for the prison and NHS.
 - The intervention may benefit long-term prisoners, who may find participation rewarding, and
25 prison staff may feel better equipped to support women who self-harm.
 - The nature of conducting a study within a prison raises challenges, including attrition and
26 effective interdisciplinary co-ordination.
27
28
29
30
31
32
33
34
35
36
37

38
39 **Key Words:** Medical skin camouflage, self-harm, scarring, women prisoners, recovery, feasibility
40 trial.
41
42

43 **INTRODUCTION**

44 **Self-harm in Women's Prisons**

45
46
47
48
49 Self-harm is defined as 'intentional self-poisoning or injury, irrespective of the apparent purpose of
50 the act'[1]. The most common methods for self-harm in women's prisons are cutting and scratching
51 followed by self-strangulation[2]. This complex behaviour is an increasing public health concern, not
52 least because of its association with acute psychological distress and increased suicide risk[2, 3].
53
54
55
56
57
58
59
60

1
2
3 Self-harm is extremely prevalent and increasing in UK prisons. In the 12 months to December 2016
4 there were 7,657 incidents of self-harm in female prisons, an increase of 4% on the previous year[4].
5
6 This is a rate of 1,987 self-harm incidents per 1,000 prisoners. Although women make up
7
8 approximately 5% of the UK prison population, they are responsible for around a fifth of all prison
9
10 self-harm[4].
11

12
13 Research has shown that living with disfigurement from non-self-harm causes can have long-term
14
15 physical and psychosocial effects, including reduced social interaction, increased social anxiety and
16
17 reduced quality of life[5, 6]. Furthermore, living with scars can be challenging in a society which
18
19 values physical attractiveness[7, 8]. It is likely that women prisoners with self-harm scarring
20
21 experience similar psychosocial difficulties e.g. low self-esteem and interpersonal problems. These
22
23 may be exacerbated by guilt and shame that women may feel because of their self-inflicted
24
25 injuries[9]. There are, however, individuals who feel ambivalent about their self-harm scars, and
26
27 whilst they may attempt to conceal scars in certain contexts, some feel confident and comfortable with
28
29 their physical appearance[10].
30
31

32 33 **Medical Skin Camouflage**

34
35 Medical skin camouflage (MSC) uses British National Formulary-listed preparations to reduce the
36
37 visibility of scarring or disfigurement[11], with the potential to restore self-esteem, and aid
38
39 recovery[12, 13, 14]. Products include skin-matched creams and powders that are waterproof, opaque
40
41 and allow adherence to textured skin. All the products are 'borderline prescription' products that are
42
43 available on NHS prescription at each prescriber's discretion. A systematic review of the use of MSC
44
45 in prisons yielded no available studies. Only a handful of published studies have evaluated the
46
47 emotional/psychological benefits of MSC and all were in dermatological diseases or burns scarring.
48
49 They report significant psychological benefit, improved social and sexual relationships and improved
50
51 employability[8, 15, 16]. Despite these potential benefits, few services offer MSC for self-harm
52
53 scarring[17].
54
55
56
57
58
59
60

1
2
3 There has been little focus on how prisoners feel about their self-harm scars and no formally
4 evaluated interventions to help women cope with any related psychosocial difficulties. This is the first
5 study to formally deliver and evaluate an MSC intervention in a women's prison. Potential benefits of
6 the intervention may include 1) increased self-esteem, confidence and quality of life; 2) empowering
7 women to take part in work and social activities they might otherwise avoid and 3) enhancing the
8 strategies and interventions that prison staff have to work with self-harm[18]. Previous work by the
9 research team has shown that there is a difficult relationship between prison staff and prisoners who
10 self-harm and that staffs feel restricted in how to help women[19]. This intervention may help staff to
11 support women with self-harm scars and promote positive staff attitudes about self-harm and its
12 management.

13
14
15
16
17
18
19
20
21
22
23
24 This study has been developed in collaboration with staff from 5 Boroughs Partnership (5BP) NHS
25 Foundation Trust who recently piloted an innovative camouflage service for service users with self-
26 harm scars[20]. The 6-month pilot found that 95% of young people who used the MSC experienced
27 improved confidence and ability to engage in activities[20]. To our knowledge, this is the first time
28 that MSC has been evaluated in a mental health service and provided as part of a recovery package.
29 The 5BP MSC service continues to be run in partnership with Changing Faces, a registered charity
30 that uses volunteers to teach the MSC techniques to people in the community. This feasibility and
31 acceptability study would provide insight into any benefits of using MSC in women's prisons and also
32 any downsides, risks or unintended consequences.

33 34 35 36 37 38 39 40 41 42 43 44 **Phase 1 and 2**

45
46 The MSC intervention and protocol used in our study were informed by the Changing Faces MSC
47 training materials[21] and modified in Phase 1 and 2 of the project. Phase 1 involved one focus group,
48 with women prisoners with experience of self-harm (n=10) and one with prison staff (n=10). Both
49 groups were conducted in safer custody meeting rooms and lasted between 60-90 minutes. The staff
50 focus group explored and refined practical aspects of delivering MSC in the prison, including details
51 of how participants would be recruited, where MSC clinics would be held and whether any MSC
52
53
54
55
56
57
58
59
60

1
2
3 items would be unsuitable for prison use. The focus group with women prisoners helped to select the
4 set of women-centred outcome measures and discussed their thoughts on long-term prisoners
5 delivering the intervention. Women said they would prefer to be trained by other prisoners,
6 particularly other women who have self-harmed. The rationale for recruiting long-term prisoners to
7 deliver the intervention was to improve the sustainability of the intervention since they are likely to
8 remain in the prison for a long time and can therefore continue training women to use MSC. Women
9 also discussed the idea of completing a weekly diary; they thought this would be a good way of
10 recording any thoughts or incidents of self-harm and some women had used a diary previously. Phase
11 2 involved adapting the MSC treatment intervention based on these focus groups, and producing the
12 training and intervention protocols. The full analysis of the focus groups will be reported in a separate
13 paper.
14
15
16
17
18
19
20
21
22
23
24
25

26 *Study Aims:*

- 27 1) To evaluate the feasibility and acceptability of a Randomised Controlled Trial (RCT) of MSC
28 for women prisoners with self-harm scarring.
29
- 30 2) To assess the feasibility and acceptability of long-term prisoners delivering the MSC
31 intervention.
32
- 33 3) To test the feasibility and acceptability of collecting a set of women-centred outcome
34 measures pre- and post-intervention, as well as a weekly self-harm diary.
35
- 36 4) To pilot follow-up of women at 12 weeks after baseline.
37
- 38 5) To test the feasibility and acceptability of collecting resource use data relating to self-harm
39 incidents.
40
41
42
43
44
45
46
47

48 **METHODS & ANALYSIS**

49 **Design**

50
51
52 This study is a feasibility pilot of an RCT, incorporating a qualitative component to assess the
53 acceptability of MSC to women prisoners and prison staff. The study is taking place in one UK closed
54
55
56
57

1
2
3 women's prison. The research is funded by the National Institute for Health Research (NIHR)
4 Research for Patient Benefit Programme (PB-PG-1013-32075). It was approved by West of Scotland
5 Research Ethics Committee (16/WS/0155). The current protocol version is Version 6 (17/05/2017).
6
7

8 9 **Sample size**

10
11 Over 6 months (January 2017 – May 2017), we aim to recruit at least 6-10 long-term women
12 prisoners to be trained in MSC. These women will then deliver the intervention to trial participants.
13
14 The long-term prisoners will not be participants in the RCT, but will instead form an integral part of
15 the research team delivering the intervention to the RCT participants.
16
17

18
19 Over eight months (January 2017 – September 2017) we aim to recruit and consent 40 women
20 prisoners to be randomised to receive either MSC or 'treatment as usual' (TAU) in a wait-list control
21 (to receive the MSC after the study period) design. Based on previous research[22] and recent figures
22 from the study prison, we estimate that there will be around 5-6 eligible women per month.
23
24
25
26
27

28 29 **Participants and recruitment procedures**

30
31 Recruitment procedures and advertisement strategies have been informed by the Phase 1 focus
32 groups. The research team will advertise the research at Safer Custody meetings attended by women
33 prisoners. Leaflets and posters will be distributed to our local collaborators in the prison for display in
34 different locations around the prison. Women will inform the local collaborators if they are interested
35 in participating. We have one member of Safer Custody staff collaborating with the researchers and a
36 woman prisoner from the Safer Custody team organising the research appointments. Prison staff will
37 assess all volunteers to determine whether they would pose a risk to the researchers or other
38 participants. Staff will also check the woman's sentence length to ensure she has enough time
39 remaining on her sentence to take part in the study. In addition, healthcare staff will review the list of
40 women to assess whether there are any health reasons why they might not be safe to participate. This
41 has been usual practice across our decade of prisoner participation in research.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Vetted/screened women will be provided with an information sheet and offered the opportunity for
4 the research team to visit, read through the sheet and answer any questions. Consent for the research
5 will be agreed at least 24 hours after the information sheet has been read.
6
7

8 9 **Inclusion/exclusion criteria**

10 11 *Phase 3:*

12
13 We aim to recruit 6-10 long-term prisoners with at least 10 years or more left on their sentence and
14 who have experience of self-harm.
15
16

17
18 Discussions with prison staff suggested that the most suitable long-term women would be those who
19 already hold a position of responsibility in the prison e.g. a peer supporter or trained Samaritan
20 listener.
21
22
23
24

25 26 *Phase 4:*

27
28 We aim to recruit 40 women prisoners screened for date of release, with sufficient time left on their
29 sentence to complete the intervention period. The women will have self-harm scarring anywhere on
30 their body that they are happy to show to others, with at least some closed wounds (to allow the MSC
31 to be applied).
32
33
34
35
36
37

38 All participants (phase 3 and 4) will be aged 18 or older and able to give written, informed consent.
39 Capacity to consent will be assessed by the experienced researchers (HM and KG) in collaboration
40 with Safer Custody and Mental Health Care contacts in the prison. Participants will be excluded from
41 the study if they are unable to provide written informed consent, or if they pose a risk to researchers
42 (as assessed by the prison).
43
44
45
46
47

48 49 **Randomisation**

50
51 In Phase 4 internet randomisation (using an internet-based programme to randomise participants;
52 www.sealedenvelope.com) will be carried out by the non-blind members of the research team, KG or
53 HM, to allocate eligible women to MSC or waitlist control. Women in the waitlist group would
54
55
56
57
58
59
60

1
2
3 receive one skin-matched prescription of MSC at the end of the research. Waitlist control has been
4
5 chosen as the comparator to give all participants an opportunity to use the MSC. Participants
6
7 randomised to the waitlist control would be aware of their allocation (figure 1).
8

9
10 **The Intervention – Medical Skin Camouflage for Self-harm scarring (adapted for delivery in a**
11 **women’s prison)**
12

13
14 **Development**
15

16
17 Outcomes of the Phase 1 focus groups informed the development of the MSC intervention materials.
18
19 In addition, two service user researchers (FE and TM) provided guidance to the research team,
20
21 focusing on whether the intervention materials were suitable in terms of readability and sensitivity.
22
23

24
25 The intervention package consists of the training manual and four additional documents. The main
26
27 training manual has been adapted from training manuals used by Changing Faces[21]. The adapted
28
29 materials have been reviewed by a representative from the charity, to ensure that all key learning and
30
31 safety points are covered.
32
33

34
35 *Manual Content*
36

37 The 34-page training manual has 13 sections that are listed and briefly described in Table 1 below.
38
39
40

41 Table 1: Sections of the training manual

Section Number	Section Name	Overview	Key Learning Point
1	Self-harm	This section aims to help women understand the different forms that self-harm can take and different reasons why women self-harm.	Different people have very different reasons for self-harming and it is therefore important to not make assumptions.
2	Working with women who self-harm in the COVER project	This section covers how to manage confidentiality and how to work with women who self-harm e.g. being respectful, don't judge the participant, the limits of confidentiality.	To manage and understand the limits of confidentiality, e.g. if she discloses something that puts her or someone else at risk, and what to do if a woman becomes upset.

3	Hygiene	This section covers how to run a hygienic skin camouflage clinic and how to keep the kit clean.	Hygiene rules to follow during an appointment.
4	Communication	This section covers communication rules, including how to manage participant expectations e.g. setting realistic expectations for what MSC can achieve.	Understanding the importance of helping the client to express their wishes and working with them to achieve the best results.
5	The Skin & Skin types	An overview of preparing the skin for application of MSC and how to ensure safe usage e.g. by checking for allergies.	How to prepare the skin and when it is not safe to use the products.
6	Overview of the kit	This section describes the items in the MSC kits and how to lay them out in a logical order.	Laying the kit out in a logical order will help the practitioner to quickly identify the products.
7	Colour Matching	This section covers colour matching. This will involve some practical activities on identifying colour tones and colour matching.	To be able to identify tones in the creams and perform a colour match.
8	Brush Technique	An overview of the brush technique and when/how to use it.	To understand when and how to use brushes.
9	Finger Technique	An overview of the finger technique and when/how to use it.	To understand when and how to use the finger technique.
10	Sponge Technique	An overview of the sponge technique and when/how to use it.	To understand when and how to use sponges.
11	Spreading Technique	An overview of the spreading technique and when/how to use it.	To understand when and how to use the spreading technique.
12	Working with powder	An overview of how to use powder to set the MSC creams.	To understand the purpose of powder, and how to apply it.
13	Completing the record card	This section covers how to complete the participant record card, including what to do with the record card after the appointment.	What to include on the record card.

Accompanying Documents

- 1) A single sheet of key learning points for long-term prisoners covering safety issues such as how to protect trial participants e.g. breaking confidentiality if a woman discloses something which suggests she or someone else is at risk of harm.
- 2) A monitoring sheet for long-term prisoners to be used in weekly meetings with the research team. The form will help to identify whether any further training or support is required.

- 3) An appointment checklist for long-term prisoners breaking down the 14 core steps in a MSC appointment, from laying out the kit, to completing a prescription record card.
- 4) A DOs and DON'Ts sheet for trial participants: this covers reminder points, including those related to safety and hygiene (e.g. always keep lids on the products) and some rules relating to continued participation in the trial (e.g. don't trade or share the products as only one prescription will be provided, added at the request of prison staff).

Delivery of the Intervention

Three stages of delivery: 1) training sessions for long-term prisoners, 2) skin camouflage clinics run by long-term prisoners for trial participants, 3) prescription of MSC products by prison healthcare.

1) Members of the research team aim to deliver a half-day training session to 6-10 long-term women prisoners. During this session, the research team will work through the training manual, answering any questions and giving practical demonstrations of colour matching, application techniques and powdering. Participants will participate in practical activities to ensure that they have understood the training and are competent in MSC. There is scope for the training time to be extended if the women require more practice.

2) The aim is that regular skin camouflage appointments will be run by the trained long-term prisoners. The appointments will be held during the core prison day and will not interfere with the women's income. All participants will be seen individually for one hour; the intervention group will be seen as soon as possible after they have been randomised and the waitlist control group will be seen after they have completed their 12-week follow-up. During this appointment, the long-term prisoner will provide the woman with information about the MSC creams and powders; including allergy checks to ensure the woman can safely use the products. The long-term prisoner will then perform a colour-match for the participant and demonstrate the application techniques. The participant will then practice applying the camouflage creams themselves until they are happy with the results. The long-term prisoner will then complete a record form to be given to healthcare.

1
2
3 3) The aim is for a nurse prescriber from healthcare to meet with all participants (the intervention
4 group at the start and the waitlist control group at the end of the research) and write a prescription for
5 1x camouflage cream and 1x camouflage powder. Women will be informed that they will only be
6 given one prescription for the duration of the study. The amount of camouflage cream required will
7 depend on the extent of the participant's scarring, but based on the 5BP pilot[20] we anticipate that
8 one prescription will be enough for a 3-month period.
9
10
11
12
13
14
15

16 Continued provision of the MSC products post-trial is not envisaged at this stage within the study
17 prison. However, all participants will be given a letter that they have the option to give to their
18 General Practitioner (GP) in the community that will detail their MSC prescription, and will
19 recommend that the product is prescribed to them.
20
21
22
23
24
25

26 **Assessing feasibility and acceptability**

27
28 We will assess the feasibility of recruiting and randomising women to MSC vs wait list and of long-
29 term prisoners delivering MSC appointments. We will examine use of the MSC, attrition (number of
30 drop-outs at each time point), and retention (the proportion of participants who complete the
31 intervention period). The feasibility of delivery in a prison setting (i.e. location, duration of training,
32 peer-delivery) and the acceptability of the intervention to women and staff will be assessed using
33 qualitative interviews and focus groups. The feasibility of undertaking a full-scale RCT of MSC for
34 women in prison will be assessed by studying recruitment (the proportion of eligible participants
35 consenting to join the study) and completeness of outcome measures at baseline, post-intervention
36 (approximately nine weeks from baseline to include the time taken to receive the MSC and 6 weeks of
37 MSC use) and at follow-up (12 weeks from baseline). We have included a 12-week follow up to
38 assess retention and attrition over a longer period of time. Data will be collected on reasons for
39 ineligibility, non-consent and dropout, including when the participant dropped out/withdrew from the
40 study.
41
42
43
44
45
46
47
48
49
50
51
52
53

54 **Outcome measures for future RCT design**

1
2
3 The aim is that all participants in both groups (MSC and waitlist control) will be asked to complete a
4 set of quantitative outcome measures at baseline (zero weeks), post-intervention (approximately nine
5 weeks later) and at follow-up (approximately 12 weeks from baseline). This will help us to assess the
6 feasibility and acceptability of these measures for a future clinical and cost-effectiveness RCT.
7
8

9
10 Outcome measures will be administered by the project manager (PM), trained research assistant (RA)
11 or research nurses from the NIHR clinical research network. The PM and the RA will be unblinded to
12 the randomisation outcome and will therefore only administer baseline measures; administration of
13 measures at any other time point by these individuals may bias results. The research nurses will be
14 blinded and will complete the post-intervention and 12-week follow-up assessments. All research
15 assessments (which we anticipate will last approximately 1 hour) will take place in a private room in
16 Safer Custody. The PM, RA or research nurse will complete a case report form for each participant;
17 recording any additional notes on each participant e.g. reasons for questionnaire non-completion.
18
19

20
21 Given the sensitive nature of some of the selected outcome measures, we have consulted with women,
22 Safer Custody staff and healthcare/mental health staff to develop procedures to protect and support
23 participants. If, at any point during a research assessment the woman becomes agitated or distressed,
24 we will ask them if they would like to take a break or if they want to resume the assessment on
25 another day. If the researcher has any concerns for the woman, they will alert the local collaborator
26 who will ensure it is dealt with accordingly using existing prison support systems. The participant
27 information sheet outlines that the researcher is obligated to inform the prison if there is a risk to the
28 participant's health, safety or wellbeing. For this study this will include reporting high suicidal
29 ideation and high risk of serious self-harm.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 We aim to administer a selection of outcome measures (see Table 2) to all participants at baseline, 9-
46 weeks and 12-weeks after baseline. Two of these measures, the Dermatology Quality of Life Index
47 (DQLi)[23] and Rosenberg Self-esteem Scale (RSES)[24], were added following focus group
48 discussions on the psychological and interpersonal impact of scars. At baseline, we also aim to use a
49 bespoke demographic and personal history questionnaire to collect relevant personal information
50 including age, ethnicity, whether they are on remand or sentenced, past experience of contact
51
52
53
54
55
56
57
58
59
60

1
2
3 psychiatric services, drug dependence and experiences of domestic violence, sexual abuse and
4 parental neglect. We aim to collect this information to check whether the two randomised groups have
5 similar backgrounds. With women's permission, our local collaborator or a research nurse will access
6 information on key forensic and clinical characteristics from CNomis, SystemOne (the prison
7 electronic medical records) and from Assessment, Care in Custody and Teamwork (ACCT)
8 documentation; these systems will be accessed by prison staff unless the researchers are granted
9 access permission. Forensic characteristics will include types of offence (violent or non-violent),
10 sentence length and stage of sentence and clinical characteristics will include psychiatric diagnosis
11 and history. We aim to administer the Deliberate Self-Harm Inventory (DSHI)[25] at baseline and
12 follow-ups: a 17-item questionnaire that assesses the history and frequency of self-harming
13 behaviours. We also aim to administer the Zanarini Rating Scale for Borderline Personality disorder
14 (ZAN-BPD) at all time points as a measure of borderline psychopathology[26].
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

Table 2: Participant Assessment Schedule

Assessment Tool	Brief Description	Time Point			
		Duration (min)	Baseline	Post-intervention	Follow-up (12 weeks)
Personal History Questionnaire	Socio-demographic/life history	5	X		
DSHI	Methods/history of self-harm	10	X	X	X
WEMWBS	Mental wellbeing	5	X	X	X
BSSI	Suicidal ideation	10	X	X	X
BDI-II	Depression	10	X	X	X
BHS	Hopelessness	5	X	X	X
DQLi	Self-harm scarring quality of life	5	X	X	X
RSES	Self-esteem	5	X	X	X
ZAN-BPD	Borderline personality disorder	5	X	X	X
EQ-5D-5L	Generic health	5	X	X	X
SF12	Generic health/quality of life	5	X	X	X
Qualitative Interview	Acceptability and feasibility	30			X
Total time burden			70	65	95
Self-harm Diary	Self-harm thoughts and incidents		Weekly from baseline to 12 weeks		

52
53
54 We aim to examine whether the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS)[27] is a
55 suitable primary outcome for a full-scale RCT. The WEMWBS is a 14-item scale of mental wellbeing
56
57

1
2
3 covering subjective wellbeing and psychological functioning, in which all items are worded positively
4 and address aspects of positive mental health. The WEMWBS has high internal consistency ($\alpha = .91$)
5 and test-retest reliability (0.83)[27]. This measure would be used to calculate study power in a full-
6
7 scale subsequent trial.
8
9

10
11
12 Becks Scale for Suicidal Ideation (BSSI)[28]: a 19-item instrument measuring intensity, duration and
13 specificity of thoughts about committing suicide. The BSSI has high internal consistency (0.89) and
14 high inter-rater reliability (0.83)[28]. The BSSI has been successfully used in a pilot trial of
15
16 Psychodynamic Interpersonal Therapy for women prisoners who self-harm[22].
17
18
19

20
21
22 Becks Depression Inventory (BDI-II)[29]: a 21-item scale measuring symptoms of depression. The
23 BDI-II has high internal consistency and a test-retest reliability ranging from 0.73 to 0.96[30].
24
25
26

27
28 Beck Hopelessness Scale (BHS)[31]: a 20-item self-report inventory designed to measure three major
29 aspects of hopelessness: feelings about future, loss of motivation and expectations. The BHS has high
30 concurrent validity (0.86) and high reliability ($\alpha = 0.91$)[31].
31
32
33

34
35
36 Prison-adapted Dermatology Quality of Life Index (DQLi)[23]: a 7-item questionnaire adapted from a
37 validated 10 item scale that has been used in over 40 different skin conditions in over 80 countries.
38
39 Test-retest reliability has been found to be high (0.99)[23].
40
41
42

43
44 Rosenberg Self-Esteem Scale (RSES)[24]: a 10-item Likert scale with items answered on a four-point
45 scale – from strongly agree to strongly disagree. The scale measures self-esteem and has been used in
46
47 prison research[32]. Internal consistency ranges from 0.77 to 0.88 and test-retest reliability ranges
48
49 from 0.82 to 0.85[24].
50
51
52

1
2
3 EQ-5D-5L[33]: a generic preference-based measure covering five domains of health-related quality of
4 life (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Test-retest reliability is
5 high and ranges from 0.78 to 0.87, with convergent validity at 0.64[34].
6
7
8
9

10 SF-12 is a shortened version of the SF-36[35], consisting of twelve questions covering eight
11 dimensions of health: physical functioning, role limitations - physical, bodily pain, general health,
12 vitality, social functioning, role limitations - emotional, and mental health. Test-retest reliability
13 ranges from 0.76 to 0.89 and relative validity ranges from 0.43 to 0.93 [34].
14
15
16
17
18
19

20 To reduce attrition, we aim to seek consent at baseline for women who have been transferred or have
21 left prison during the study period to be followed up in person at other prisons or in a public place in
22 the community, following a lone worker policy.
23
24
25
26
27

28 In addition to the outcome measures listed above, we also aim to ask trial participants to complete a
29 weekly diary every week from their baseline assessment. Prison staff and women prisoners in the
30 Phase 1 focus groups proposed the use of a weekly diary; some of the women had completed a diary
31 of self-harm thoughts and events in the past and found it helpful. The research team will collect the
32 diary each week. The diary will ask questions about any thoughts or acts of self-harm that have
33 occurred during the week and any life events that have impacted on their self-harm during the week.
34 Women will also have a free-text space to add additional comments.
35
36
37
38
39
40
41
42
43

44 We also aim to pilot the collection of resource use data. This will be collected using the Secure
45 Facilities Service Use Schedule (SFSUS)[36] and a bespoke resource use questionnaire. Resource use
46 data is likely to be extracted by the local collaborator from systems such as CNomis and Officers logs.
47 Prison staff will redact any confidential information. We also aim to use these systems, together with
48 SystemOne, to extract data on self-harm incidents that occurred during the intervention. If we
49 successfully extract the data we will then triangulate prison records of self-harm incidents with
50
51
52
53
54
55
56
57
58
59
60

1
2
3 women's self-reported incidents. We will record the time taken by prison staff and healthcare staff to
4
5 extract this information.
6
7

8
9 To inform a future cost analysis, we also aim to record the time spent by Changing Faces training the
10
11 researchers in medical skin camouflage, time spent by the research team training long-term prisoners
12
13 to become skin camouflage practitioners, time spent by long-term prisoners delivering the
14
15 intervention, and quantities of MSC products prescribed.
16
17

18 **Qualitative Data**

19
20 We aim to conduct interviews with all women in the MSC group (n=20) at the end of the study, to
21
22 assess the acceptability of the intervention to service users. The interviews with women will explore
23
24 their views on applying MSC, how long it stays on for, how useful they found it and any positive or
25
26 negative effects on their everyday life, mood, self-esteem and self-confidence. The topic guides have
27
28 been developed in consultation with two service user researchers and informed by outcomes of the
29
30 Phase 1 focus group.
31
32

33
34 We also aim to interview the long-term prisoners to assess their experiences of being an MSC
35
36 practitioner, in terms of the acceptability of the training, mentoring/support from the research team
37
38 and any benefits or difficulties working with participants.
39
40

41
42 In addition, we aim to conduct a focus group with prison staff from different disciplines (including
43
44 Safer Custody staff, prison officers and healthcare staff) that have been in contact with women
45
46 involved in the trial. The focus group would explore acceptability of the intervention from a staff
47
48 perspective, including what they thought about prisoner-delivery of the MSC intervention and
49
50 whether the intervention has had a positive, or negative, impact on their job or their relationships with
51
52 women prisoners. All interviews and the focus group will use semi-structured topic guides with open-
53
54 ended questions that should enable us to explore in-depth the aspects of the intervention that worked
55
56 well, the aspects that did not work well, and things that could be improved. With permission from
57
58

1
2
3 participants, interviews will be audio-recorded. All recordings will then be transcribed verbatim and
4
5 analysed using thematic analysis[37].
6
7

8
9 We aim to assess fidelity to the MSC intervention by a) observing the long-term prisoners at the end
10
11 of training covering one of our service user researcher's scars; b) audio recording 10% of the training
12
13 sessions which will be rated for fidelity to the training manual by an independent researcher.
14
15

16 **Data Analysis**

17 *Quantitative analyses*

18
19
20
21
22
23 We shall compare means before and after treatment using descriptive statistics, including standard
24
25 deviations and confidence intervals for outcome variables to inform sample size estimates for a future
26
27 RCT. We will also present descriptive statistics on recruitment and retention of participants in both
28
29 groups, including reasons for dropout at different stages.
30
31

32
33 We shall assess the feasibility and relevance of both the EQ-5D-5L and SF-12 for the prison
34
35 population through correlation between changes from baseline to follow-up of these and other piloted
36
37 measures (WEMWS; BSSI; BDI; BHS; RSES; ZAN-BPD); and examination of completion rates.

38
39 Descriptive analysis of Health Related Quality of Life data will also inform the suitability of the
40
41 measures for future clinical and economic evaluations of the intervention.
42

43
44 Resource use collection will also be assessed through time taken to complete questionnaires,
45
46 completion rates and ability to obtain included resource-use categories to inform suitability of
47
48 resource use categories in a future economic evaluation. Descriptive analysis of resource use data will
49
50 also inform future trial design.

51 *Qualitative data*

52
53
54
55
56
57
58
59
60 Qualitative data will be analysed using thematic analysis[37]; analysis which will be conducted by the
RA and PM and checked for accuracy by an independent researcher. Preliminary codes and categories

1
2
3 are assigned to the text[38] and emergent themes subject to constant comparison and examined for
4
5 goodness-of-fit until a final set of key themes identified[39]. Adopting an inductive, iterative
6
7 approach, data analysis will commence with the first interview.
8

9 10 **Data Entry & Storage**

11
12 Written consent forms and completed questionnaires will be removed straight to the University of
13
14 Manchester. Participants will be given a unique participant number that will be used on questionnaires
15
16 and the electronic database. A password-protected document will link participant names and numbers.
17
18 Any identifying personal data (e.g. consent forms) will be stored separately from other research data.
19
20 In the University of Manchester this will mean storage in the locked limited access corridor.
21
22 Electronic databases will be stored on an encrypted space on University of Manchester computers.
23
24 The RA would enter all data and the PM will carry out 10% checks for accuracy.
25

26 27 **ETHICS & DISSEMINATION**

28 29 **Adverse events**

30
31 All participants will be women who have a history of self-harm. Therefore, self-harm incidents are an
32
33 expected event and not necessarily a serious adverse event. All adverse events, including incidents of
34
35 self-harm, will be recorded and reported to the project manager. In consultation with prison staff and
36
37 the prisoner, the research team will assess the seriousness of the adverse event and whether it is
38
39 related to project participation; events that are judged as serious and unrelated will be reported to the
40
41 sponsor only. Events judged as serious and related to project participation will be reported to the
42
43 research sponsor, host NHS trust and West of Scotland Research Ethics Committee (REC).
44
45

46 47 **Dissemination**

48
49 We aim for our findings to be disseminated to prisoners, prison staff and to the wider stakeholder
50
51 (academic and clinical) community via showcase events at the study prison, presentations at national
52
53 and international conferences, journal publications, safer custody and prison governor meetings and
54
55 university/NHS trust communications.
56
57

Discussion

Despite the large number of women in prison whom self-harm (or who have self-harmed in the past and are living with scarring), there are little/no evidence-based interventions which aim to improve self-esteem, confidence and wellbeing. This low-cost intervention has the potential to improve women's mood and how they feel about themselves.

Our Phase 1 focus groups suggested that many women prisoners who repeat self-harm struggle on a regular basis with negative feelings about their scars e.g. they have to cover them in front of others/family for fear of being judged adversely or upsetting them; they are a constant reminder of bad times or they lack confidence in their bodies because of scars. A prisoner-delivered MSC intervention could reduce such distress women prisoners experience and help them re-integrate into the community without the additional burden of being judged because of their scars.

This intervention was implemented successfully in a community mental health service. We, therefore, anticipate that, with the support of prison staff and long-term prisoners, COVER will provide a beneficial resource to improve wellbeing in an often-neglected population.

Engaging long-term prisoners in the delivery of MSC clinics should increase the sustainability of the intervention if it were to be commissioned in future and provide meaningful work for women prisoners, offering a valuable opportunity to improve relationships between prisoners and contribute towards a therapeutic community with the prison. Peer support schemes, such as the Samaritan's Listener scheme which runs across many UK prisons are increasingly popular, enabling prisoners to develop a range of transferable skills and reducing the burden of distress and self-harm management for prison staff. If successfully implemented, COVER will run alongside these peer support services and provide additional help for women who self-harm.

Authors' contributions

KA and TW conceived and designed the study and applied for funding. KG drafted the original protocol. KA, KG & HM led the development of the prison-modified MSC intervention; are

1
2
3 responsible for drafting and revising the protocol manuscript; have given final approval for the
4 version to be published and are accountable for all aspects of the work. HM and BD led the write-up
5 of the protocol manuscript under the supervision of KG. KG is the research project manager and
6
7 HM/BD are the research assistants on the study. KA, KG, HM, JP, TW, SR, LR, JS & RM co-led the
8 development of COVER and participated in the design of the study. KA and JS provide the senior
9 academic oversight on all aspects of the feasibility study. KG, HM and BD lead the Patient and Public
10 Involvement (PPI). FE and TM have provided expert by experience input throughout the project. All
11 authors read and approved the final protocol manuscript.
12
13
14
15
16
17
18
19

20 **Acknowledgements**

21 We would like to thank the service users, prison staff and healthcare professionals who participated in
22 the focus groups during phase one of the study. We would like to thank the COVER project steering
23 group for their ongoing input and support. We would also like to thank the prison governor and our
24 local collaborators in the prison for their support.
25
26
27
28
29
30

31 **Funding**

32 This project was funded by the National Institute for Health Research (NIHR)
33 Research for Patient Benefit Programme (reference PB-PG-1013-32075). This article presents
34 independent research funded by the NIHR. The views and opinions expressed therein are those of the
35 authors and do not necessarily reflect those of the RfPB programme, NIHR, NHS or the Department
36 of Health. The study sponsor is The University of Manchester and the host NHS Trust is Greater
37 Manchester Mental Health NHS Foundation Trust.
38
39
40
41
42
43
44
45
46
47

48 **Competing Interests**

49 The authors declare that they have no competing interests.
50
51
52
53

54 **Consent for Publication**

55 Not applicable.
56
57
58
59
60

Ethical Approval and Consent to Participate

Ethical approval has been granted by the West of Scotland Research Ethics Committee 3, REC reference: 16/WS/0155. Recruitment is currently ongoing; to date, 30 participants have entered the Phase 4 trial.

Availability of Data and Materials

Not applicable

Author Details

¹Centre for Women's Mental Health, Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane Building, Manchester, M13 9PL. ²Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane Building, Manchester, M13 9PL. ³Department of Psychology, School of Human & Health Sciences, University of Huddersfield, Edith Key Building, Queensgate, Huddersfield, HD1 3DH. ⁴5 Boroughs Partnership NHS Foundation Trust. ⁵Lancashire Care NHS Foundation Trust, Preston, United Kingdom. ⁶Centre for Mental Health and Risk, Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane Building, Manchester, M13 9PL. ⁷Mental Health and Criminal Justice Group, University of Central Lancashire, Preston, UK. ⁸Manchester Centre for Health Economics, Institute of Population Health, Division of Population Health, Health Services Research and Primary Care, University of Manchester, Jean McFarlane Building, Manchester, M13 9PL. ⁹Offender Health Research Network, Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane Building, Manchester, M13 9PL.

Figure 1. Consort diagram.

References

1 National Collaborating Centre for Mental Health. Self-Harm: The Short-Term Physical and Psychological Management and Secondary Prevention of Self-Harm in Primary and Secondary Care. London, England: National Institute for Clinical Excellence, 2004.

1
2
3
4
5 2 Hawton K, Arensman E, Townsend E, et al. Deliberate Self Harm: Systematic Review of Efficacy
6 of Psychosocial and Pharmacological Treatments in Preventing Repetition. *Brit Med J*
7 1998;317(7156):441-7 doi:10.1136/bmj.317.7156.441 [published 15 August 1998].
8
9

10
11 3 Marzano L, Fazel S, Rivlin A, et al. Psychiatric disorders in women prisoners who have engaged in
12 near-lethal self-harm: case-control study. *Br J Psychiatry* 2010;197:219-26 doi:
13 10.1192/bjp.bp.109.075424.
14
15

16
17 4 Ministry of Justice. Safer in custody statistics England and Wales: Deaths in custody to March
18 2016, Assaults and self-harm in custody to December 2015. London: Ministry of Justice, 2016.
19
20

21
22 5 Van Loey N, Van Son M. Psychopathology and psychological problems in patients with burn scars:
23 epidemiology and management. *Am J Clin Dermatol* 2003;4:245-72 doi:10.2165/00128071-
24 200304040-00004.
25
26

27
28 6 Brown B, McKenna S, Siddhi K, et al. The hidden cost of skin scars: quality of life after skin
29 scarring. *J Plast Reconstr Aesthet Surg Open* 2008;61:1049-58 doi:10.1016/j.bjps.2008.03.020
30 [published 9 July 2008].
31
32

33
34 7 Rumsey N, Clarke A, Musa M. Altered Body Image: The Psychosocial Needs of Patients. *Br J*
35 *Community Nurs* 2002;7(11):563-6 doi:10.12968/bjcn.2002.7.11.10886 [published November 2002].
36
37

38
39 8 Levy L, Emer J. Emotional Benefit of Cosmetic Camouflage in the Treatment of Facial Skin
40 Conditions: Personal Experience and Review. *Clin Cosmet Investig Dermatol* 2012;5:173-82 doi:
41 10.2147/CCID.S33860 [published 1 November 2012].
42
43

44
45 9 Leibenluft E, Gardner D, Cowdry R. The inner experience of the borderline self-mutilator. *J Pers*
46 *Disord* 1987;1:317-24 doi:10.1521/pedi.1987.1.4.317.
47
48

49
50 10 Chandler A. Narrating the self-injured body. *Med Humanit* 2014;40:111-16 doi:10.1136/medhum-
51 2013-010488.
52
53

54
55 11 McMichael L. Skin Camouflage. *Brit Med J* 2012;344:d7921 doi:10.1136/bmj.d7921 [published 5
56 January 2012].
57
58

1
2
3
4
5 12 Holme S, Beattie P, Fleming C. Cosmetic Camouflage Advice Improves Quality of Life. *Br J Dermatol* 2002;147(5):946-9 doi:10.1046/j.1365-2133.2002.04900.x [published 1 November 2002].
6
7

8
9
10 13 Green L. The Effect of Skin Conditions on Patients' Quality of Life. *Nurs Stand* 2010;25(9):48-56
11 doi:10.7748/ns2010.11.25.9.48.c8078 [published 03 November 2010].
12

13
14 14 Kent G. Testing a Model of Disfigurement: Effects of a Skin Camouflage Service on Well-Being
15 and Appearance Anxiety. *Psychol Health* 2002;17(3):377-86 doi:10.1080/08870440290029601
16 [published online 27 October 2010].
17
18

19
20 15 Tanioka M, Yamamoto Y, Kato M, et al. Camouflage for Patients with Vitiligo Vulgaris Improved
21 their Quality of Life. *J Cosmet Dermatol* 2010;9(1):72-5 doi:10.1111/j.1473-2165.2010.00479.x
22 [published 22 February 2010].
23
24

25
26 16 Hayashi N, Imori M, Yanagisawa M, et al. Make-up Improves the Quality of Life of Acne Patients
27 without Aggravating Acne Eruptions during Treatments. *Eur J Dermatol* 2005;15(4):284-7.
28
29

30
31 17 McConochie L, Pearson E. Development of a Nurse-Led Skin Camouflage Clinic. *Nurs Stand*
32 2006;20(24):74, 6, 8 passim doi:10.7748/ns.20.24.74.s59 [published February 2006].
33
34

35
36 18 Walker T, Shaw J, Ranote S, et al. Medical Skin Camouflage: A Recovery Intervention for Female
37 Prisoners who Self-Harm? *Crim Behav Ment Health* 2014;24(5):317-20 doi:10.1002/cbm.1943
38 [published 03 November 2014].
39
40

41
42 19 Kenning C, Cooper J, Short V, et al. Prison staff and women prisoner's views on self-harm; their
43 implications for service delivery and development: A qualitative study. *Crim Behav Ment Health*
44 2010;20(4):274-84 doi:10.1002/cbm.777 [published online 05 July 2010].
45
46

47
48 20 Ranote S. Skin camouflage service: A first for mental health; Innovation to implementation. Talk
49 presented at Self-harm in Women's Prisons Conference; 2016; University of Manchester.
50
51

52
53 21 Changing Faces. Skin Camouflage Practitioner Training Trainer's Practical Course Manual for
54 COVER Project. London, England: Changing Faces, 2015.
55
56

- 1
2
3
4
5 22 Walker T, Shaw J, Turpin C, et al. The WORSHIP II study: a pilot of psychodynamic
6 interpersonaltherapy with women offenders who self-harm. *J Forens Psychiatry Psychol*
7 2017;28(2):158-71 doi:10.1080/14789949.2017.1301529 [published online 08 March 2017].
8
9
10
11 23 Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for
12 routine clinical use. *Clin Exp Dermatol* 1994;19:210-6 doi:10.1111/j.1365-2230.1994.tb01167.x
13 [published May 1994].
14
15
16
17 24 Rosenberg M. Society and the adolescent self-image. Princeton, N.J: Princeton University Press;
18 1965.
19
20
21
22 25 Gratz KL. Measurement of Deliberate Self-Harm: Preliminary Data on the Deliberate Self-Harm
23 Inventory. *J Psychopathol Behav Assess* 2001;23(4):253-63 doi: 10.1023/A:1012779403943
24 [published December 2001].
25
26
27
28 26 Zanarini MC. Zanarini Rating Scale For Borderline Personality Disorder (ZAN-BPD): A
29 Continuous Measure of DSM-IV Borderline Psychopathology. *J Pers Disord* 2003;17(3):233-242 doi:
30 10.1521/pedi.17.3.233.22147 [published July 2003].
31
32
33
34 27 Tennant R, Hiller L, Fishwick R, et al. The Warwick-Edinburgh Mental Well-being Scale
35 (WEMWBS): development and UK validation. *Health Qual Life Outcomes* 2007;5(63)
36 doi:10.1186/1477-7525-5-63 [published 27 November 2007].
37
38
39
40 28 Beck AT, Kovacs M, Weissman A. Assessment of Suicidal Intention - Scale for Suicide Ideation. *J*
41 *Consult Clin Psych* 1979;47(2):343-52 doi:10.1037/0022-006X.47.2.343[published April 1979].
42
43
44
45 29 Beck AT, Steer RA, Brown GK. Manual for the BDI-II. San Antonio: TX: Psychological
46 Corporation; 1996.
47
48
49
50 30 Wang YP, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: a
51 comprehensive review. *Rev Bras Psiquiatr* 2013;35:416-31 doi:10.1590/1516-4446-2012-1048
52 [published online 23 December 2013].
53
54
55
56
57
58
59
60

1
2
3 31 Beck AT, Weissman A, Lester D, et al. The Measurement of Pessimism: The Hopelessness Scale.
4 *J Consult Clin Psych* 1974;42(6):861-5 doi:10.1037/h0037562 [published December 1974].
5

6
7
8 32 Boduszek D, Shevlin M, Mallett J, et al. Dimensionality and construct validity of the Rosenberg
9 Self-Esteem Scale within a sample of recidivistic prisoners. *J Crim Psychol* 2012;2(1):19-25 doi:
10 10.1108/20093821211210468.
11

12
13
14 33 Gusi N, Olivares PR, Rajendram R. The EQ-5D Health-Related Quality of Life Questionnaire.
15 Springer. USA, New York. 2010:87-99.
16

17
18
19 34 Haywood KL, Garratt AM, Dziedzic K, et al. Generic measures of health-related quality of life in
20 ankylosing spondylitis: reliability, validity and responsiveness. *Rheumatology* 2002;41:1380-87 doi:
21 10.1093/rheumatology/41.12.1380 [published 01 December 2002].
22

23
24
25 35 Ware JJ, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and
26 preliminary tests of reliability and validity. *Med Care* 1996;34(3):220-33 doi:10.2307/3766749
27 [published April 1996].
28

29
30
31 36 Barrett B, Byford S. Collecting service use data for economic evaluation in DSPD populations:
32 development of the Secure Facilities Service Use Schedule. *Br J Psychiatry* 2007;190(suppl. 49):s79-
33 s79 doi:10.1192/bjp.190.5.s75 [published online 03 January 2018].
34

35
36
37 37 Braun V, Clark V. Using Thematic Analysis in Psychology. *Qual Res Psychol* 2006;3(2):77-101
38 doi:10.1191/1478088706qp063oa [published online 21 July 2008].
39

40
41
42 38 Boyatzis R. Transforming Qualitative Information: Thematic Analysis and Code Development.
43 California: Sage 1998.
44

45
46
47 39 Mays N, Pope C. Qualitative research: Rigor and qualitative research. *Brit Med J* 1995;311:109-12
48 doi:10.1136/bmj.311.6997.109 [published 08 July 1995].
49




Figure 1. Consort diagram.

239x310mm (600 x 600 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description
Administrative information		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry
	2b	All items from the World Health Organization Trial Registration Data Set
Protocol version	3	Date and version identifier
Funding	4	Sources and types of financial, material, and other support
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors
	5b	Name and contact information for the trial sponsor
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
Introduction		
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
	6b	Explanation for choice of comparators
Objectives	7	Specific objectives or hypotheses
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions
---------------------	-----	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

1			
2	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central
3	concealment		telephone; sequentially numbered, opaque, sealed envelopes),
4	mechanism		describing any steps to conceal the sequence until interventions are
5			assigned
6			
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,
8			and who will assign participants to interventions
9			
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial
11	(masking)		participants, care providers, outcome assessors, data analysts), and
12			how
13			
14		17b	If blinded, circumstances under which unblinding is permissible, and
15			procedure for revealing a participant's allocated intervention during
16			the trial
17			

18 **Methods: Data collection, management, and analysis**

19			
20	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other
21	methods		trial data, including any related processes to promote data quality (eg,
22			duplicate measurements, training of assessors) and a description of
23			study instruments (eg, questionnaires, laboratory tests) along with
24			their reliability and validity, if known. Reference to where data
25			collection forms can be found, if not in the protocol
26			
27			
28		18b	Plans to promote participant retention and complete follow-up,
29			including list of any outcome data to be collected for participants who
30			discontinue or deviate from intervention protocols
31			
32	Data	19	Plans for data entry, coding, security, and storage, including any
33	management		related processes to promote data quality (eg, double data entry;
34			range checks for data values). Reference to where details of data
35			management procedures can be found, if not in the protocol
36			
37	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.
38	methods		Reference to where other details of the statistical analysis plan can be
39			found, if not in the protocol
40			
41			
42		20b	Methods for any additional analyses (eg, subgroup and adjusted
43			analyses)
44			
45		20c	Definition of analysis population relating to protocol non-adherence
46			(eg, as randomised analysis), and any statistical methods to handle
47			missing data (eg, multiple imputation)
48			

49 **Methods: Monitoring**

50			
51	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role
52			and reporting structure; statement of whether it is independent from
53			the sponsor and competing interests; and reference to where further
54			details about its charter can be found, if not in the protocol.
55			Alternatively, an explanation of why a DMC is not needed
56			
57			
58			
59			
60			

1		21b	Description of any interim analyses and stopping guidelines, including
2			who will have access to these interim results and make the final
3			decision to terminate the trial
4			
5	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and
6			spontaneously reported adverse events and other unintended effects
7			of trial interventions or trial conduct
8			
9			
10	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and
11			whether the process will be independent from investigators and the
12			sponsor
13			

Ethics and dissemination

14			
15			
16	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board
17			(REC/IRB) approval
18			
19	Protocol amendments	25	Plans for communicating important protocol modifications (eg,
20			changes to eligibility criteria, outcomes, analyses) to relevant parties
21			(eg, investigators, REC/IRBs, trial participants, trial registries, journals,
22			regulators)
23			
24	Consent or assent	26a	Who will obtain informed consent or assent from potential trial
25			participants or authorised surrogates, and how (see Item 32)
26			
27		26b	Additional consent provisions for collection and use of participant data
28			and biological specimens in ancillary studies, if applicable
29			
30	Confidentiality	27	How personal information about potential and enrolled participants will
31			be collected, shared, and maintained in order to protect confidentiality
32			before, during, and after the trial
33			
34			
35	Declaration of interests	28	Financial and other competing interests for principal investigators for
36			the overall trial and each study site
37			
38	Access to data	29	Statement of who will have access to the final trial dataset, and
39			disclosure of contractual agreements that limit such access for
40			investigators
41			
42	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for
43			compensation to those who suffer harm from trial participation
44			
45	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to
46			participants, healthcare professionals, the public, and other relevant
47			groups (eg, via publication, reporting in results databases, or other
48			data sharing arrangements), including any publication restrictions
49			
50		31b	Authorship eligibility guidelines and any intended use of professional
51			writers
52			
53		31c	Plans, if any, for granting public access to the full protocol, participant-
54			level dataset, and statistical code
55			
56			
57			
58			
59			
60			

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

BMJ Open

An acceptability and feasibility pilot randomised controlled trial of medical skin camouflage for recovery of women prisoners with self-harm scarring (COVER): the study protocol.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021891.R1
Article Type:	Protocol
Date Submitted by the Author:	08-Jun-2018
Complete List of Authors:	<p>Mitchell, Heather; University of Manchester, Centre for Women's Mental Health; Greater Manchester Mental Health NHS Foundation Trust, Psychological Research</p> <p>Abel, Kathryn; University of Manchester, Centre for Women's Mental Health; Greater Manchester Mental Health NHS Foundation Trust, Psychological Research</p> <p>Dunlop, Brendan; University of Manchester, Centre for Women's Mental Health; Greater Manchester Mental Health NHS Foundation Trust, Psychological Research</p> <p>Walker, Tammi; University of Huddersfield, Department of Psychology</p> <p>Ranote, Sandeep; North West Boroughs Healthcare NHS Foundation Trust</p> <p>Robinson, Louise; Lancashire Care NHS Foundation Trust; University of Manchester, Centre for Women's Mental Health</p> <p>Edgar, Fiona; University of Manchester, Centre for Women's Mental Health; University of Central Lancashire, Mental Health and Criminal Justice Group</p> <p>Millington, Tracy; University of Manchester, Centre for Women's Mental Health</p> <p>Meacock, Rachel; Univ Manchester,</p> <p>Shaw, Jennifer; University of Manchester, Offender Health Research Network</p> <p>Gutridge, Kerry; University of Manchester, Centre for Women's Mental Health</p>
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Health economics, Legal and forensic medicine, Mental health, Public health
Keywords:	Medical skin camouflage, self-harm, scarring, women prisoners, recovery, feasibility trial

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3 **An acceptability and feasibility pilot randomised controlled trial of medical skin camouflage for**
4 **recovery of women prisoners with self-harm scarring (COVER): the study protocol.**
5
6
7

8 Heather Mitchell,^{1,2} Professor Kathryn Abel,^{1,2} Brendan J Dunlop,^{1,2} Dr Tammi Walker,³ Dr Sandeep
9 Ranote,⁴ Dr Louise Robinson,^{5,6} Fiona Edgar,^{1,7} Tracy Millington,¹ Rachel Meacock,⁸ Professor
10 Jenny Shaw,⁹ Dr Kerry Guttridge.¹
11
12
13
14

15 **Heather Mitchell, BA**

16
17 ¹Centre for Women's Mental Health, Division of Psychology and Mental Health, School of Health
18 Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane
19 Building, Manchester, M13 9PL and ²Greater Manchester Mental Health NHS Foundation Trust,
20 Bury New Road, Prestwich, M25 3BL, United Kingdom.
21
22 heather.mitchell@manchester.ac.uk
23
24
25

26 **Professor Kathryn Abel, PhD, MB ChB**

27
28 ¹Centre for Women's Mental Health, Division of Psychology and Mental Health, School of Health
29 Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane
30 Building, Manchester, M13 9PL and ²Greater Manchester Mental Health NHS Foundation Trust,
31 Bury New Road, Prestwich, M25 3BL, United Kingdom.
32
33 kathryn.abel@manchester.ac.uk
34
35
36

37 **Brendan J Dunlop, BSc**

38
39 ¹Centre for Women's Mental Health, Division of Psychology and Mental Health, School of Health
40 Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane
41 Building, Manchester, M13 9PL and ²Greater Manchester Mental Health NHS Foundation Trust,
42 Bury New Road, Prestwich, M25 3BL, United Kingdom.
43
44 brendan.dunlop@manchester.ac.uk
45
46
47

48 **Dr Tammi Walker, PhD**

49
50 ³Department of Psychology, School of Human & Health Sciences, University of Huddersfield, Edith
51 Key Building, Queensgate, Huddersfield, HD1 3DH, United Kingdom.
52
53 t.walker@hud.ac.uk
54
55

56 **Dr Sandeep Ranote, MB ChB**

57
58 ⁴Boroughs Partnership NHS Foundation Trust, Hollins Park Hospital, Hollins Lane,
59 Winwick, Warrington, WA2 8WA, United Kingdom.
60

1
2
3 sandeep.ranote@5bp.nhs.uk
4
5

6 **Dr Louise Robinson, MB ChB**
7

8 ⁵Lancashire Care NHS Foundation Trust, Preston, United Kingdom and ⁶Centre for Mental Health
9 and Risk, Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology,
10 Medicine and Health, University of Manchester, Jean McFarlane Building, Manchester, M13 9PL,
11 United Kingdom.
12

13
14 louise.robinson@manchester.ac.uk
15
16

17 **Fiona Edgar**
18

19 ¹Centre for Women's Mental Health, Division of Psychology and Mental Health, School of Health
20 Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane
21 Building, Manchester, M13 9PL, United Kingdom and ⁷Mental Health and Criminal Justice Group,
22 University of Central Lancashire, Preston, United Kingdom .
23

24
25 FEdgar@uclan.ac.uk
26
27

28 **Tracy Millington**
29

30 ¹Centre for Women's Mental Health, Division of Psychology and Mental Health, School of Health
31 Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane
32 Building, Manchester, M13 9PL, United Kingdom.
33

34
35 7milliebob@gmail.com
36
37

38 **Rachel Meacock, MA**
39

40 ⁸Manchester Centre for Health Economics, Institute of Population Health, Division of Population
41 Health, Health Services Research and Primary Care, University of Manchester, Jean McFarlane
42 Building, Manchester, M13 9PL, United Kingdom.
43

44
45 rachel.meacock@manchester.ac.uk
46
47

48 **Professor Jenny Shaw, PhD, MB ChB**
49

50 ⁹Offender Health Research Network, Division of Psychology and Mental Health, School of Health
51 Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane
52 Building, Manchester, M13 9PL, United Kingdom.
53

54
55 jennifer.j.shaw@manchester.ac.uk
56

57 **Dr Kerry Gutridge, PhD (corresponding author)**
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

¹Centre for Women's Mental Health, Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane Building, Manchester, M13 9PL, United Kingdom.

kerry.gutridge@manchester.ac.uk

Word count: 5,342

Abstract

Introduction

Self-harm in prison is a major public health concern. Less than 5% of UK prisoners are women, but they carry out more than a fifth of prison self-harm. Scars resulting from self-harm can be traumatising and stigmatising, yet there has been little focus on recovery of women prisoners with self-harm scarring. Medical skin camouflage (MSC) clinics treat individuals with disfiguring skin conditions, with evidence of improved wellbeing, self-esteem and social interactions. Only one community study has piloted the use of MSC for self-harm scarring.

Methods & Analysis

We describe an acceptability and feasibility pilot randomised controlled trial; the first to examine MSC for women prisoners who self-harm. We aim to randomise 20-25 women prisoners to a 6-week MSC intervention and 20-25 to a wait-list control (to receive the MSC after the study period). We aim to train at least 6-10 long-term prisoners with personal experience of self-harm to deliver the intervention. Pre- and post-intervention, we will pilot collection of women-centred outcomes, including quality of life, wellbeing and self-esteem. We will pilot collection of self-harm incidents during the intervention, resources used to manage/treat self-harm and follow-up of women at 12-weeks from baseline. Data on recruitment, retention and drop-out will be recorded. We aim for the acceptability of the intervention to prison staff and women prisoners to be explored in qualitative interviews and focus groups.

Ethics and dissemination

Ethical approval for COVER has been granted by the North East – York REC for Phase 1 and 2 (REC reference: 16/NE/0030) and West of Scotland REC 3 for Phase 3 and 4 (REF: 16/WS/0155). Informed consent will be the primary consideration; it will be made clear that participation will have no effect on life in prison or eligibility for parole. Due to the nature of the study, disclosures of serious self-harm may need to be reported to prison officials. We aim for findings to be disseminated via events at the study prison, presentations at national/international conferences, journal publications, prison governor meetings and university/NHS trust communications.

Trial Registration

The trial is registered on clinicaltrials.gov (identifier: NCT02638974).

Strengths & limitations of this study

- COVER is the first pilot randomised controlled trial of the use of medical skin camouflage for women who self-harm in prison
- The study has been co-designed with experts-by-experience to test the delivery of a peer-led intervention
- As a pilot, the sample size for the study is small, however, the research is designed to gather data on the feasibility and acceptability of delivering the intervention in prison rather than the efficacy of the intervention
- The study will take place in one prison within the women's estate.

Key Words: Medical skin camouflage, self-harm, scarring, women prisoners, recovery, feasibility trial.

INTRODUCTION

Self-harm in Women's Prisons

Self-harm is defined as 'intentional self-poisoning or injury, irrespective of the apparent purpose of the act'[1]. The most common methods for self-harm in women's prisons are cutting and scratching

1
2
3 followed by self-strangulation[2]. This complex behaviour is an increasing public health concern, not
4
5 least because of its association with acute psychological distress and increased suicide risk[2, 3].
6
7

8 Self-harm is extremely prevalent and increasing in UK prisons. In the 12 months to December 2016
9
10 there were 7,657 incidents of self-harm in female prisons, an increase of 4% on the previous year[4].
11
12 This is a rate of 1,987 self-harm incidents per 1,000 prisoners. Although women make up
13
14 approximately 5% of the UK prison population, they are responsible for around a fifth of all prison
15
16 self-harm[4].
17

18
19 Research has shown that living with disfigurement from non-self-harm causes can have long-term
20
21 physical and psychosocial effects, including reduced social interaction, increased social anxiety and
22
23 reduced quality of life[5, 6]. Furthermore, living with scars can be challenging in a society which
24
25 values physical attractiveness[7, 8]. It is likely that women prisoners with self-harm scarring
26
27 experience similar psychosocial difficulties e.g. low self-esteem and interpersonal problems. These
28
29 may be exacerbated by guilt and shame that women may feel because of their self-inflicted
30
31 injuries[9]. There are, however, individuals who feel ambivalent about their self-harm scars, and
32
33 whilst they may attempt to conceal scars in certain contexts, some feel confident and comfortable with
34
35 their physical appearance[10].
36
37
38
39

40 41 **Medical Skin Camouflage**

42 Medical skin camouflage (MSC) uses British National Formulary-listed preparations to reduce the
43
44 visibility of scarring or disfigurement[11], with the potential to restore self-esteem, and aid
45
46 recovery[12, 13, 14]. Products include skin-matched creams and powders that are waterproof, opaque
47
48 and allow adherence to textured skin. All the products are 'borderline prescription' products that are
49
50 available on NHS prescription at each prescriber's discretion. A systematic review of the use of MSC
51
52 in prisons yielded no available studies. Only a handful of published studies have evaluated the
53
54 emotional/psychological benefits of MSC and all were in dermatological diseases or burns scarring.
55
56 They report significant psychological benefit, improved social and sexual relationships and improved
57
58
59
60

1
2
3 employability[8, 15, 16]. Despite these potential benefits, few services offer MSC for self-harm
4 scarring[17].
5
6
7
8

9 There has been little focus on how prisoners feel about their self-harm scars and no formally
10 evaluated interventions to help women cope with any related psychosocial difficulties. This is the first
11 study to formally deliver and evaluate an MSC intervention in a women's prison. Potential benefits of
12 the intervention may include 1) increased self-esteem, confidence and quality of life; 2) empowering
13 women to take part in work and social activities they might otherwise avoid and 3) enhancing the
14 strategies and interventions that prison staff have to work with self-harm[18]. Previous work by the
15 research team has shown that there is a difficult relationship between prison staff and prisoners who
16 self-harm and that staffs feel restricted in how to help women[19]. This intervention may help staff to
17 support women with self-harm scars and promote positive staff attitudes about self-harm and its
18 management.
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 This study has been developed in collaboration with staff from 5 Boroughs Partnership (5BP) NHS
34 Foundation Trust who recently piloted an innovative camouflage service for service users with self-
35 harm scars[20]. The 6-month pilot found that 95% of young people who used the MSC experienced
36 improved confidence and ability to engage in activities[20]. To our knowledge, this is the first time
37 that MSC has been evaluated in a mental health service and provided as part of a recovery package.
38 The 5BP MSC service continues to be run in partnership with Changing Faces, a registered charity
39 that uses volunteers to teach the MSC techniques to people in the community. This feasibility and
40 acceptability study would provide insight into any benefits of using MSC in women's prisons and also
41 any downsides, risks or unintended consequences.
42
43
44
45
46
47
48
49
50
51
52
53

54 **Phase 1 and 2**

55 The MSC intervention and protocol used in our study were informed by the Changing Faces MSC
56 training materials[21] and modified in Phase 1 and 2 of the project. Phase 1 involved one focus group,
57 with women prisoners with experience of self-harm (n=10) and one with prison staff (n=10). Both
58
59
60

1
2
3 groups were conducted in safer custody meeting rooms and lasted between 60-90 minutes. The staff
4 focus group explored and refined practical aspects of delivering MSC in the prison, including details
5 of how participants would be recruited, where MSC clinics would be held and whether any MSC
6 items would be unsuitable for prison use. The focus group with women prisoners helped to select the
7 set of women-centred outcome measures and discussed their thoughts on long-term prisoners
8 delivering the intervention. Women said they would prefer to be trained by other prisoners,
9 particularly other women who have self-harmed. The rationale for recruiting long-term prisoners to
10 deliver the intervention was to improve the sustainability of the intervention since they are likely to
11 remain in the prison for a long time and can therefore continue training women to use MSC. Women
12 also discussed the idea of completing a weekly diary; they thought this would be a good way of
13 recording any thoughts or incidents of self-harm and some women had used a diary previously. Phase
14 2 involved adapting the MSC treatment intervention based on these focus groups, and producing the
15 training and intervention protocols. The full analysis of the focus groups will be reported in a separate
16 paper.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 *Study Aims:*

- 36 1) To evaluate the feasibility and acceptability of a Randomised Controlled Trial (RCT) of MSC
37 for women prisoners with self-harm scarring.
38
- 39 2) To assess the feasibility and acceptability of long-term prisoners delivering the MSC
40 intervention.
41
- 42 3) To test the feasibility and acceptability of collecting a set of women-centred outcome
43 measures pre- and post-intervention, as well as a weekly self-harm diary.
44
- 45 4) To pilot follow-up of women at 12 weeks after baseline.
46
- 47 5) To test the feasibility and acceptability of collecting resource use data relating to self-harm
48 incidents.
49
50
51
52
53
54
55
56
57

58 **METHODS & ANALYSIS**
59
60

Design

This study is a feasibility pilot of an RCT, incorporating a qualitative component to assess the acceptability of MSC to women prisoners and prison staff. The study is taking place in one UK closed women's prison. The research is funded by the National Institute for Health Research (NIHR) Research for Patient Benefit Programme (PB-PG-1013-32075). It was approved by North East – York REC for Phase 1 and 2 (REC reference: 16/NE/0030) and West of Scotland REC for Phase 3 and 4 (16/WS/0155). The current protocol version is Version 6 (17/05/2017).

Patient and public involvement

At the development phase of the research, a patient and public involvement group was conducted in one women's prison using a Patient and Public Involvement bursary from the NIHR Research Design Service North West. During this group women from the prison, who had self-harm scarring, contributed towards the research topic development through discussion of the possible impact of medical skin camouflage. This informed the outcome measures for the research and the topic guides/interview schedules for the qualitative work. In phase 1 of the research, women in prison with self-harm scarring, helped refine the design of the research assessing the burden of involvement in a randomised controlled trial.

Two experts-by-experience joined the research team at the start of the research and contributed towards the design of all the materials for participants. In phase 3, one of these experts-by-experience will help train the long-term prisoners to be medical skin camouflage practitioners having agreed to allow the women to practice application of the MSC on her self-harm scars. Another of our experts-by-experience, who is a trained qualitative researcher, analysed the phase 1 focus group data and will co-facilitate the staff focus group at the end of the research. A current prisoner, who works in Safer Custody has agreed to help to organise the participants' appointments in the prison and will sit on the project steering group. At the end of the research our experts-by-experience will help us to design a dissemination event for the women in prison that will involve presentations on the research outcomes.

1
2
3 A plain English summary of the research will also be provided to women in the prison. We will also
4
5 disseminate the research on the closed prison radio system.
6
7

8 **Sample size**

9

10 Over 6 months (January 2017 – May 2017), we aim to recruit at least 6-10 long-term women
11
12 prisoners to be trained in MSC. These women will then deliver the intervention to trial participants.
13
14 The long-term prisoners will not be participants in the RCT, but will instead form an integral part of
15
16 the research team delivering the intervention to the RCT participants.
17
18

19
20 Over seventeen months (January 2017 – May 2018) we aim to recruit and consent 40-50 women
21
22 prisoners to be randomised to receive either MSC or ‘treatment as usual’ (TAU) in a wait-list control
23
24 (to receive the MSC after the study period) design. Based on previous research[22] and recent figures
25
26 from the study prison, we estimate that there will be around 5-6 eligible women per month. The
27
28 sample size is based on a prediction that approximately half of these eligible women will be interested
29
30 in the research.
31
32

33 **Participants and recruitment procedures**

34

35
36 Recruitment procedures and advertisement strategies have been informed by the Phase 1 focus
37
38 groups. The research team will advertise the research at Safer Custody meetings attended by women
39
40 prisoners. Leaflets and posters will be distributed to our local collaborators in the prison for display in
41
42 different locations around the prison. Women will inform the local collaborators if they are interested
43
44 in participating. We have one member of Safer Custody staff collaborating with the researchers and a
45
46 woman prisoner from the Safer Custody team organising the research appointments. Prison staff will
47
48 assess all volunteers to determine whether they would pose a risk to the researchers or other
49
50 participants. Staff will also check the woman’s sentence length to ensure she has enough time
51
52 remaining on her sentence to take part in the study. In addition, healthcare staff will review the list of
53
54 women to assess whether there are any health reasons why they might not be safe to participate. This
55
56 has been usual practice across our decade of prisoner participation in research.
57
58
59
60

Vetted/screened women will be provided with an information sheet and offered the opportunity for the research team to visit, read through the sheet and answer any questions. Consent for the research will be agreed at least 24 hours after the information sheet has been read.

Inclusion/exclusion criteria

Phase 3:

We aim to recruit 6-10 long-term prisoners with at least 10 years or more left on their sentence and who have experience of self-harm.

Discussions with prison staff suggested that the most suitable long-term women would be those who already hold a position of responsibility in the prison e.g. a peer supporter or trained Samaritan listener.

Phase 4:

We aim to recruit 40-50 women prisoners screened for date of release, with sufficient time left on their sentence to complete the intervention period. The women will have self-harm scarring anywhere on their body that they are happy to show to others, with at least some closed wounds (to allow the MSC to be applied).

All participants (phase 3 and 4) will be aged 18 or older and able to give written, informed consent. Capacity to consent will be assessed by the experienced researchers (HM and KG) in collaboration with Safer Custody and Mental Health Care contacts in the prison. Participants will be excluded from the study if they are unable to provide written informed consent, or if they pose a risk to researchers (as assessed by the prison).

Randomisation

In Phase 4 internet randomisation (using an internet-based programme to randomise participants; www.sealedenvelope.com) will be carried out by the non-blind members of the research team, KG or HM, to allocate eligible women to MSC or waitlist control. Women in the waitlist group would

1
2
3 receive one skin-matched prescription of MSC at the end of the research. Waitlist control has been
4
5 chosen as the comparator to give all participants an opportunity to use the MSC. Participants
6
7 randomised to the waitlist control would be aware of their allocation (figure 1).
8
9

10 **The Intervention – Medical Skin Camouflage for Self-harm scarring (adapted for delivery in a** 11 12 **women’s prison)**

13 **Development**

14
15
16
17
18 Outcomes of the Phase 1 focus groups informed the development of the MSC intervention materials.
19
20 In addition, two service user researchers (FE and TM) provided guidance to the research team,
21
22 focusing on whether the intervention materials were suitable in terms of readability and sensitivity.
23
24
25

26
27 The intervention package consists of the training manual and four additional documents. The main
28
29 training manual has been adapted from training manuals used by Changing Faces[21]. The adapted
30
31 materials have been reviewed by a representative from the charity, to ensure that all key learning and
32
33 safety points are covered.
34
35
36

37 *Manual Content*

38
39 The 34-page training manual has 13 sections that are listed and briefly described in Table 1 below.
40
41
42
43

44 **Table 1: Sections of the training manual**

45 Section Number	46 Section Name	47 Overview	48 Key Learning Point
49 1	50 Self-harm	51 This section aims to help women understand the 52 different forms that self-harm can take and 53 different reasons why women self-harm.	54 Different people have very different 55 reasons for self-harming and it is 56 therefore important to not make 57 assumptions.
58 2	59 Working with 60 women who self-harm in the COVER project	This section covers how to manage confidentiality and how to work with women who self-harm e.g. being respectful, don't judge the participant, the limits of confidentiality.	To manage and understand the limits of confidentiality, e.g. if she discloses something that puts her or someone else at risk, and what to do if a woman becomes upset.

3	Hygiene	This section covers how to run a hygienic skin camouflage clinic and how to keep the kit clean.	Hygiene rules to follow during an appointment.
4	Communication	This section covers communication rules, including how to manage participant expectations e.g. setting realistic expectations for what MSC can achieve.	Understanding the importance of helping the client to express their wishes and working with them to achieve the best results.
5	The Skin & Skin types	An overview of preparing the skin for application of MSC and how to ensure safe usage e.g. by checking for allergies.	How to prepare the skin and when it is not safe to use the products.
6	Overview of the kit	This section describes the items in the MSC kits and how to lay them out in a logical order.	Laying the kit out in a logical order will help the practitioner to quickly identify the products.
7	Colour Matching	This section covers colour matching. This will involve some practical activities on identifying colour tones and colour matching.	To be able to identify tones in the creams and perform a colour match.
8	Brush Technique	An overview of the brush technique and when/how to use it.	To understand when and how to use brushes.
9	Finger Technique	An overview of the finger technique and when/how to use it.	To understand when and how to use the finger technique.
10	Sponge Technique	An overview of the sponge technique and when/how to use it.	To understand when and how to use sponges.
11	Spreading Technique	An overview of the spreading technique and when/how to use it.	To understand when and how to use the spreading technique.
12	Working with powder	An overview of how to use powder to set the MSC creams.	To understand the purpose of powder, and how to apply it.
13	Completing the record card	This section covers how to complete the participant record card, including what to do with the record card after the appointment.	What to include on the record card.

Accompanying Documents

- 1) A single sheet of key learning points for long-term prisoners covering safety issues such as how to protect trial participants e.g. breaking confidentiality if a woman discloses something which suggests she or someone else is at risk of harm.
- 2) A monitoring sheet for long-term prisoners to be used in weekly meetings with the research team. The form will help to identify whether any further training or support is required.

- 3) An appointment checklist for long-term prisoners breaking down the 14 core steps in a MSC appointment, from laying out the kit, to completing a prescription record card.
- 4) A DOs and DON'Ts sheet for trial participants: this covers reminder points, including those related to safety and hygiene (e.g. always keep lids on the products) and some rules relating to continued participation in the trial (e.g. don't trade or share the products as only one prescription will be provided, added at the request of prison staff).

Delivery of the Intervention

Three stages of delivery: 1) training sessions for long-term prisoners, 2) skin camouflage clinics run by long-term prisoners for trial participants, 3) prescription of MSC products by prison healthcare.

1) Members of the research team aim to deliver a half-day group training session to 6-10 long-term women prisoners. During this session, the research team will work through the training manual, answering any questions and giving practical demonstrations of colour matching, application techniques and powdering. Participants will participate in practical activities to ensure that they have understood the training and are competent in MSC. There is scope for the training time to be extended if the women require more practice.

2) The aim is that regular skin camouflage appointments will be run by the trained long-term prisoners. The appointments will be held during the core prison day and will not interfere with the women's income. All participants will be seen individually for one hour; the intervention group will be seen as soon as possible after they have been randomised and the waitlist control group will be seen after they have completed their 12-week follow-up. During this appointment, the long-term prisoner will provide the woman with information about the MSC creams and powders; including allergy checks to ensure the woman can safely use the products. The long-term prisoner will then perform a colour-match for the participant and demonstrate the application techniques. The participant will then practice applying the camouflage creams themselves until they are happy with the results. The long-term prisoner will then complete a record form to be given to healthcare.

1
2
3 3) The aim is for a nurse prescriber from healthcare to meet with all participants (the intervention
4 group at the start and the waitlist control group at the end of the research) and write a prescription for
5 1x camouflage cream and 1x camouflage powder. Women will be informed that they will only be
6 given one prescription for the duration of the study. The amount of camouflage cream required will
7 depend on the extent of the participant's scarring, but based on the 5BP pilot[20] we anticipate that
8 one prescription will be enough for a 3-month period.
9
10
11
12
13
14
15
16
17

18 Continued provision of the MSC products post-trial is not envisaged at this stage within the study
19 prison. However, all participants will be given a letter that they have the option to give to their
20 General Practitioner (GP) in the community that will detail their MSC prescription, and will
21 recommend that the product is prescribed to them.
22
23
24
25
26
27

28 **Assessing feasibility and acceptability**

29
30 We will assess the feasibility of recruiting and randomising women to MSC vs wait list and of long-
31 term prisoners delivering MSC appointments. We will examine use of the MSC, attrition (number of
32 drop-outs at each time point), and retention (the proportion of participants who complete the
33 intervention period). The feasibility of delivery in a prison setting (i.e. location, duration of training,
34 peer-delivery) and the acceptability of the intervention to women and staff will be assessed using
35 qualitative interviews and focus groups. The feasibility of undertaking a full-scale RCT of MSC for
36 women in prison will be assessed by studying recruitment (the proportion of eligible participants
37 consenting to join the study) and completeness of outcome measures at baseline, post-intervention
38 (approximately nine weeks from baseline to include the time taken to receive the MSC and 6 weeks of
39 MSC use) and at follow-up (12 weeks from baseline). We have included a 12-week follow up to
40 assess retention and attrition over a longer period of time. Data will be collected on reasons for
41 ineligibility, non-consent and dropout, including when the participant dropped out/withdrew from the
42 study.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

58 **Outcome measures for future RCT design**

1
2
3 The aim is that all participants in both groups (MSC and waitlist control) will be asked to complete a
4 set of quantitative outcome measures at baseline (zero weeks), post-intervention (approximately nine
5 weeks later) and at follow-up (approximately 12 weeks from baseline). This will help us to assess the
6 feasibility and acceptability of these measures for a future clinical and cost-effectiveness RCT.
7
8

9
10
11 Outcome measures will be administered by the project manager (PM), trained research assistant (RA)
12 or research nurses from the NIHR clinical research network. The PM and the RA will be unblinded to
13 the randomisation outcome and will therefore only administer baseline measures; administration of
14 measures at any other time point by these individuals may bias results. The research nurses will be
15 blinded and will complete the post-intervention and 12-week follow-up assessments. All research
16 assessments (which we anticipate will last approximately 1 hour) will take place in a private room in
17 Safer Custody. The PM, RA or research nurse will complete a case report form for each participant;
18 recording any additional notes on each participant e.g. reasons for questionnaire non-completion.
19

20
21
22 Given the sensitive nature of some of the selected outcome measures, we have consulted with women,
23 Safer Custody staff and healthcare/mental health staff to develop procedures to protect and support
24 participants. If, at any point during a research assessment the woman becomes agitated or distressed,
25 we will ask them if they would like to take a break or if they want to resume the assessment on
26 another day. If the researcher has any concerns for the woman, they will alert the local collaborator
27 who will ensure it is dealt with accordingly using existing prison support systems. The participant
28 information sheet outlines that the researcher is obligated to inform the prison if there is a risk to the
29 participant's health, safety or wellbeing. For this study this will include reporting high suicidal
30 ideation and high risk of serious self-harm.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 We aim to administer a selection of outcome measures (see Table 2) to all participants at baseline, 9-
49 weeks and 12-weeks after baseline. Two of these measures, the Dermatology Quality of Life Index
50 (DQLi)[23] and Rosenberg Self-esteem Scale (RSES)[24], were added following focus group
51 discussions on the psychological and interpersonal impact of scars. At baseline, we also aim to use a
52 bespoke demographic and personal history questionnaire to collect relevant personal information
53 including age, ethnicity, whether they are on remand or sentenced, past experience of contact
54
55
56
57
58
59
60

1
2
3 psychiatric services, drug dependence and experiences of domestic violence, sexual abuse and
4 parental neglect. We aim to collect this information to check whether the two randomised groups have
5 similar backgrounds. With women's permission, our local collaborator or a research nurse will access
6 information on key forensic and clinical characteristics from CNomis, SystemOne (the prison
7 electronic medical records) and from Assessment, Care in Custody and Teamwork (ACCT)
8 documentation; these systems will be accessed by prison staff unless the researchers are granted
9 access permission. Forensic characteristics will include types of offence (violent or non-violent),
10 sentence length and stage of sentence and clinical characteristics will include psychiatric diagnosis
11 and history. We aim to administer the Deliberate Self-Harm Inventory (DSHI)[25] at baseline and
12 follow-ups: a 17-item questionnaire that assesses the history and frequency of self-harming
13 behaviours. We also aim to administer the Zanarini Rating Scale for Borderline Personality disorder
14 (ZAN-BPD) at all time points as a measure of borderline psychopathology[26].
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 Table 2: Participant Assessment Schedule

Assessment Tool	Brief Description	Time Point			
		Duration (min)	Baseline	Post-intervention	Follow-up (12 weeks)
Personal History Questionnaire	Socio-demographic/life history	5	X		
DSHI	Methods/history of self-harm	10	X	X	X
WEMWBS	Mental wellbeing	5	X	X	X
BSSI	Suicidal ideation	10	X	X	X
BDI-II	Depression	10	X	X	X
BHS	Hopelessness	5	X	X	X
DQLi	Self-harm scarring quality of life	5	X	X	X
RSES	Self-esteem	5	X	X	X
ZAN-BPD	Borderline personality disorder	5	X	X	X
EQ-5D-5L	Generic health	5	X	X	X
SF12	Generic health/quality of life	5	X	X	X
Qualitative Interview	Acceptability and feasibility	30			X
Total time burden			70	65	95
Self-harm Diary	Self-harm thoughts and incidents	Weekly from baseline to 12 weeks			

56
57 We aim to examine whether the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS)[27] is a
58 suitable primary outcome for a full-scale RCT. The WEMWBS is a 14-item scale of mental wellbeing
59
60

1
2
3 covering subjective wellbeing and psychological functioning, in which all items are worded positively
4 and address aspects of positive mental health. The WEMWBS has high internal consistency ($\alpha = .91$)
5 and test-retest reliability (0.83)[27]. This measure would be used to calculate study power in a full-
6 scale subsequent trial.
7
8
9
10

11
12
13
14 Becks Scale for Suicidal Ideation (BSSI)[28]: a 19-item instrument measuring intensity, duration and
15 specificity of thoughts about committing suicide. The BSSI has high internal consistency (0.89) and
16 high inter-rater reliability (0.83)[28]. The BSSI has been successfully used in a pilot trial of
17
18 Psychodynamic Interpersonal Therapy for women prisoners who self-harm[22].
19
20
21
22

23
24 Becks Depression Inventory (BDI-II)[29]: a 21-item scale measuring symptoms of depression. The
25 BDI-II has high internal consistency and a test-retest reliability ranging from 0.73 to 0.96[30].
26
27
28
29

30
31 Beck Hopelessness Scale (BHS)[31]: a 20-item self-report inventory designed to measure three major
32 aspects of hopelessness: feelings about future, loss of motivation and expectations. The BHS has high
33 concurrent validity (0.86) and high reliability ($\alpha = 0.91$)[31].
34
35
36
37

38
39 Prison-adapted Dermatology Quality of Life Index (DQLi)[23]: a 7-item questionnaire adapted from a
40 validated 10 item scale that has been used in over 40 different skin conditions in over 80 countries.
41
42 Test-retest reliability has been found to be high (0.99)[23].
43
44
45

46
47 Rosenberg Self-Esteem Scale (RSES)[24]: a 10-item Likert scale with items answered on a four-point
48 scale – from strongly agree to strongly disagree. The scale measures self-esteem and has been used in
49
50 prison research[32]. Internal consistency ranges from 0.77 to 0.88 and test-retest reliability ranges
51
52 from 0.82 to 0.85[24].
53
54
55
56
57
58
59
60

1
2
3 EQ-5D-5L[33]: a generic preference-based measure covering five domains of health-related quality of
4 life (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Test-retest reliability is
5 high and ranges from 0.78 to 0.87, with convergent validity at 0.64[34].
6
7
8
9

10
11 SF-12 is a shortened version of the SF-36[35], consisting of twelve questions covering eight
12 dimensions of health: physical functioning, role limitations - physical, bodily pain, general health,
13 vitality, social functioning, role limitations - emotional, and mental health. Test-retest reliability
14 ranges from 0.76 to 0.89 and relative validity ranges from 0.43 to 0.93 [34].
15
16
17
18
19
20
21

22 To reduce attrition, we aim to seek consent at baseline for women who have been transferred or have
23 left prison during the study period to be followed up in person at other prisons or in a public place in
24 the community, following a lone worker policy.
25
26
27
28
29

30 In addition to the outcome measures listed above, we also aim to ask trial participants to complete a
31 weekly diary every week from their baseline assessment. Prison staff and women prisoners in the
32 Phase 1 focus groups proposed the use of a weekly diary; some of the women had completed a diary
33 of self-harm thoughts and events in the past and found it helpful. The research team will collect the
34 diary each week. The diary will ask questions about any thoughts or acts of self-harm that have
35 occurred during the week and any life events that have impacted on their self-harm during the week.
36
37
38
39
40
41
42
43 Women will also have a free-text space to add additional comments.
44
45
46
47

48 We also aim to pilot the collection of resource use data so that we can determine if it is feasible to
49 gather this data in a larger trial, with a view to calculating the cost of treatment in comparison to usual
50 care. This will be collected using the Secure Facilities Service Use Schedule (SFSUS)[36] and a
51 bespoke resource use questionnaire. Resource use data is likely to be extracted by the local
52 collaborator from systems such as CNomis and Officers logs. Prison staff will redact any confidential
53 information. We also aim to use these systems, together with SystemOne, to extract data on self-harm
54 incidents that occurred during the intervention. If we successfully extract the data we will then
55
56
57
58
59
60

1
2
3 triangulate prison records of self-harm incidents with women's self-reported incidents. We will record
4
5 the time taken by prison staff and healthcare staff to extract this information.
6
7

8
9 To inform a future cost analysis, we also aim to record the time spent by Changing Faces training the
10
11 researchers in medical skin camouflage, time spent by the research team training long-term prisoners
12
13 to become skin camouflage practitioners, time spent by long-term prisoners delivering the
14
15 intervention, and quantities of MSC products prescribed.
16
17

18 19 20 **Qualitative Data**

21
22 We aim to conduct interviews with all women in the MSC group (n=20) at the end of the study, to
23
24 assess the acceptability of the intervention to service users. The interviews with women will explore
25
26 their views on applying MSC, how long it stays on for, how useful they found it and any positive or
27
28 negative effects on their everyday life, mood, self-esteem and self-confidence. The topic guides have
29
30 been developed in consultation with two service user researchers and informed by outcomes of the
31
32 Phase 1 focus group.
33
34

35
36 We also aim to interview the long-term prisoners to assess their experiences of being an MSC
37
38 practitioner, in terms of the acceptability of the training, mentoring/support from the research team
39
40 and any benefits or difficulties working with participants.
41
42
43

44
45 In addition, we aim to conduct a focus group with prison staff from different disciplines (including
46
47 Safer Custody staff, prison officers and healthcare staff) that have been in contact with women
48
49 involved in the trial. The focus group would explore acceptability of the intervention from a staff
50
51 perspective, including what they thought about prisoner-delivery of the MSC intervention and
52
53 whether the intervention has had a positive, or negative, impact on their job or their relationships with
54
55 women prisoners. All interviews and the focus group will use semi-structured topic guides with open-
56
57 ended questions that should enable us to explore in-depth the aspects of the intervention that worked
58
59 well, the aspects that did not work well, and things that could be improved. With permission from
60

1
2
3 participants, interviews will be audio-recorded. All recordings will then be transcribed verbatim and
4
5 analysed using thematic analysis[37].
6
7
8

9 We aim to assess fidelity to the MSC intervention by a) observing the long-term prisoners at the end
10 of training covering one of our service user researcher's scars; b) audio recording 10% of the training
11 sessions which will be rated for fidelity to the training manual by an independent researcher.
12
13
14
15

16 17 **Data Analysis**

18 19 *Quantitative analyses*

20
21
22 We shall compare means before and after treatment using descriptive statistics, including standard
23 deviations and confidence intervals for outcome variables to inform sample size estimates for a future
24 RCT. We will also present descriptive statistics on recruitment and retention of participants in both
25 groups, including reasons for dropout at different stages.
26
27
28
29
30
31
32

33
34 We shall assess the feasibility and relevance of both the EQ-5D-5L and SF-12 for the prison
35 population through correlation between changes from baseline to follow-up of these and other piloted
36 measures (WEMWS; BSSI; BDI; BHS; RSES; ZAN-BPD); and examination of completion rates.
37
38
39

40 Descriptive analysis of Health Related Quality of Life data will also inform the suitability of the
41 measures for future clinical and economic evaluations of the intervention.
42
43
44

45 Resource use collection will also be assessed through time taken to complete questionnaires,
46 completion rates and ability to obtain included resource-use categories to inform suitability of
47 resource use categories in a future economic evaluation. Descriptive analysis of resource use data will
48 also inform future trial design.
49
50
51
52
53

54 55 *Qualitative data*

56
57 Qualitative data will be analysed using thematic analysis[37]; analysis which will be conducted by the
58 RA and PM and checked for accuracy by an independent researcher. Preliminary codes and categories
59
60

1
2
3 are assigned to the text[38] and emergent themes subject to constant comparison and examined for
4
5 goodness-of-fit until a final set of key themes identified[39]. Adopting an inductive, iterative
6
7 approach, data analysis will commence with the first interview.
8
9

10 **Data Entry & Storage**

11
12
13 Written consent forms and completed questionnaires will be removed straight to the University of
14
15 Manchester. Participants will be given a unique participant number that will be used on questionnaires
16
17 and the electronic database. A password-protected document will link participant names and numbers.
18
19 Any identifying personal data (e.g. consent forms) will be stored separately from other research data.
20
21 In the University of Manchester this will mean storage in the locked limited access corridor.
22
23 Electronic databases will be stored on an encrypted space on University of Manchester computers.
24
25 The RA would enter all data and the PM will carry out 10% checks for accuracy.
26
27
28

29 **ETHICS & DISSEMINATION**

30
31
32 Ethical approval for COVER was granted by the North East – York REC for Phase 1 and 2 (REC
33
34 reference: 16/NE/0030) and West of Scotland REC 3 for Phase 3 and 4 (REF: 16/WS/0155).
35
36

37 **Adverse events**

38
39 All participants will be women who have a history of self-harm. Therefore, self-harm incidents are an
40
41 expected event and not necessarily a serious adverse event. All adverse events, including incidents of
42
43 self-harm, will be recorded and reported to the project manager. In consultation with prison staff and
44
45 the prisoner, the research team will assess the seriousness of the adverse event and whether it is
46
47 related to project participation; events that are judged as serious and unrelated will be reported to the
48
49 sponsor only. Events judged as serious and related to project participation will be reported to the
50
51 research sponsor, host NHS trust and West of Scotland Research Ethics Committee (REC).
52
53

54 **Dissemination**

55
56
57 We aim for our findings to be disseminated to prisoners, prison staff and to the wider stakeholder
58
59 (academic and clinical) community via showcase events at the study prison, presentations at national
60

1
2
3 and international conferences, journal publications, safer custody and prison governor meetings and
4 university/NHS trust communications. During dissemination, we will hold discussions with key
5
6 personnel from NHS England and HMPPS regarding future provision of the intervention.
7
8
9

10 **Discussion**

11
12
13 Despite the large number of women in prison whom self-harm (or who have self-harmed in the past
14 and are living with scarring), there are little/no evidence-based interventions which aim to improve
15 self-esteem, confidence and wellbeing. This low-cost intervention has the potential. to improve
16
17 women's mood and how they feel about themselves.
18
19
20

21
22 Our Phase 1 focus groups suggested that many women prisoners who repeat self-harm struggle on a
23 regular basis with negative feelings about their scars e.g. they have to cover them in front of others/
24 family for fear of being judged adversely or upsetting them; they are a constant reminder of bad times
25 or they lack confidence in their bodies because of scars. A prisoner-delivered MSC intervention could
26
27 reduce such distress women prisoners experience and help them re-integrate into the community
28
29 without the additional burden of being judged because of their scars.
30
31
32
33
34
35

36 This intervention was implemented successfully in a community mental health service. We, therefore,
37 anticipate that, with the support of prison staff and long-term prisoners, COVER will provide a
38
39 beneficial resource to improve wellbeing in an often-neglected population.
40
41
42

43 Engaging long-term prisoners in the delivery of MSC clinics should increase the sustainability of the
44 intervention if it were to be commissioned in future and provide meaningful work for women
45
46 prisoners, offering a valuable opportunity to improve relationships between prisoners and contribute
47
48 towards a therapeutic community with the prison. Peer support schemes, such as the Samaritan's
49
50 Listener scheme which runs across many UK prisons are increasingly popular, enabling prisoners to
51
52 develop a range of transferable skills and reducing the burden of distress and self-harm management
53
54 for prison staff. If successfully implemented, COVER will run alongside these peer support services
55
56 and provide additional help for women who self-harm.
57
58
59
60

Authors' contributions

KA and TW conceived and designed the study and applied for funding. KG drafted the original protocol. KA, KG & HM led the development of the prison-modified MSC intervention; are responsible for drafting and revising the protocol manuscript; have given final approval for the version to be published and are accountable for all aspects of the work. HM and BD led the write-up of the protocol manuscript under the supervision of KG. KG is the research project manager and HM/BD are the research assistants on the study. KA, KG, HM, TW, SR, LR, JS & RM co-led the development of COVER and participated in the design of the study. KA and JS provide the senior academic oversight on all aspects of the feasibility study. KG, HM and BD lead the Patient and Public Involvement (PPI). FE and TM have provided expert by experience input throughout the project. All authors read and approved the final protocol manuscript.

Acknowledgements

We would like to thank the service users, prison staff and healthcare professionals who participated in the focus groups during phase one of the study. We would like to thank Fiona Edgar and Tracey Millington, our experts-by-experience for their valuable insights and contributions and the COVER project steering group for their on-going input and support. We would also like to thank the prison governor and our local collaborators in the prison for their support.

Funding

This project was funded by the National Institute for Health Research (NIHR) Research for Patient Benefit Programme (reference PB-PG-1013-32075). This article presents independent research funded by the NIHR. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the RfPB programme, NIHR, NHS or the Department of Health.

1
2
3 The study sponsor is The University of Manchester and the host NHS Trust is Greater Manchester
4
5 Mental Health NHS Foundation Trust.
6
7
8

9 **Competing Interests**

10
11 The authors declare that they have no competing interests.
12
13

14 **Consent for Publication**

15
16 Not applicable.
17
18
19

20 **Ethical Approval and Consent to Participate**

21
22 Ethical approval has been granted by the West of Scotland Research Ethics Committee 3, REC
23
24 reference: 16/WS/0155. Recruitment is currently on-going; to date, 30 participants have entered the
25
26 Phase 4 trial.
27
28
29

30 **Availability of Data and Materials**

31
32 Not applicable.
33
34
35
36
37
38

39 **Author Details**

40
41 ¹Centre for Women's Mental Health, Division of Psychology and Mental Health, School of Health
42 Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane
43 Building, Manchester, M13 9PL. ²Division of Psychology and Mental Health, School of Health
44 Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane
45 Building, Manchester, M13 9PL. ³Department of Psychology, School of Human & Health Sciences,
46 University of Huddersfield, Edith Key Building, Queensgate, Huddersfield, HD1 3DH. ⁴5 Boroughs
47 Partnership NHS Foundation Trust. ⁵Lancashire Care NHS Foundation Trust, Preston, United
48 Kingdom. ⁶Centre for Mental Health and Risk, Division of Psychology and Mental Health, School of
49 Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Jean McFarlane
50 Building, Manchester, M13 9PL. ⁷Mental Health and Criminal Justice Group, University of Central
51 Lancashire, Preston, UK. ⁸Manchester Centre for Health Economics, Institute of Population Health,
52 Division of Population Health, Health Services Research and Primary Care, University of Manchester,
53 Jean McFarlane Building, Manchester, M13 9PL. ⁹Offender Health Research Network, Division of
54
55
56
57
58
59
60

Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health,
University of Manchester, Jean McFarlane Building, Manchester, M13 9PL.

Figure 1. Consort diagram.

References

- 1 National Collaborating Centre for Mental Health. Self-Harm: The Short-Term Physical and Psychological Management and Secondary Prevention of Self-Harm in Primary and Secondary Care. London, England: National Institute for Clinical Excellence, 2004.
- 2 Hawton K, Arensman E, Townsend E, et al. Deliberate Self Harm: Systematic Review of Efficacy of Psychosocial and Pharmacological Treatments in Preventing Repetition. *Brit Med J* 1998;317(7156):441-7 doi:10.1136/bmj.317.7156.441 [published 15 August 1998].
- 3 Marzano L, Fazel S, Rivlin A, et al. Psychiatric disorders in women prisoners who have engaged in near-lethal self-harm: case-control study. *Br J Psychiatry* 2010;197:219-26 doi: 10.1192/bjp.bp.109.075424.
- 4 Ministry of Justice. Safer in custody statistics England and Wales: Deaths in custody to March 2016, Assaults and self-harm in custody to December 2015. London: Ministry of Justice, 2016.
- 5 Van Loey N, Van Son M. Psychopathology and psychological problems in patients with burn scars: epidemiology and management. *Am J Clin Dermatol* 2003;4:245-72 doi:10.2165/00128071-200304040-00004.
- 6 Brown B, McKenna S, Siddhi K, et al. The hidden cost of skin scars: quality of life after skin scarring. *J Plast Reconstr Aesthet Surg Open* 2008;61:1049-58 doi:10.1016/j.bjps.2008.03.020 [published 9 July 2008].
- 7 Rumsey N, Clarke A, Musa M. Altered Body Image: The Psychosocial Needs of Patients. *Br J Community Nurs* 2002;7(11):563-6 doi:10.12968/bjcn.2002.7.11.10886 [published November 2002].
- 8 Levy L, Emer J. Emotional Benefit of Cosmetic Camouflage in the Treatment of Facial Skin Conditions: Personal Experience and Review. *Clin Cosmet Investig Dermatol* 2012;5:173-82 doi: 10.2147/CCID.S33860 [published 1 November 2012].

- 1
2
3
4
5 9 Leibenluft E, Gardner D, Cowdry R. The inner experience of the borderline self-mutilator. *J Pers*
6 *Disord* 1987;1:317-24 doi:10.1521/pedi.1987.1.4.317.
7
8
9
10 10 Chandler A. Narrating the self-injured body. *Med Humanit* 2014;40:111-16 doi:10.1136/medhum-
11 2013-010488.
12
13
14
15 11 McMichael L. Skin Camouflage. *Brit Med J* 2012;344:d7921 doi:10.1136/bmj.d7921 [published 5
16 January 2012].
17
18
19
20
21 12 Holme S, Beattie P, Fleming C. Cosmetic Camouflage Advice Improves Quality of Life. *Br J*
22 *Dermatol* 2002;147(5):946-9 doi:10.1046/j.1365-2133.2002.04900.x [published 1 November 2002].
23
24
25
26 13 Green L. The Effect of Skin Conditions on Patients' Quality of Life. *Nurs Stand* 2010;25(9):48-56
27 doi:10.7748/ns2010.11.25.9.48.c8078 [published 03 November 2010].
28
29
30
31 14 Kent G. Testing a Model of Disfigurement: Effects of a Skin Camouflage Service on Well-Being
32 and Appearance Anxiety. *Psychol Health* 2002;17(3):377-86 doi:10.1080/08870440290029601
33 [published online 27 October 2010].
34
35
36
37
38 15 Tanioka M, Yamamoto Y, Kato M, et al. Camouflage for Patients with Vitiligo Vulgaris Improved
39 their Quality of Life. *J Cosmet Dermatol* 2010;9(1):72-5 doi:10.1111/j.1473-2165.2010.00479.x
40 [published 22 February 2010].
41
42
43
44 16 Hayashi N, Imori M, Yanagisawa M, et al. Make-up Improves the Quality of Life of Acne Patients
45 without Aggravating Acne Eruptions during Treatments. *Eur J Dermatol* 2005;15(4):284-7.
46
47
48
49 17 McConochie L, Pearson E. Development of a Nurse-Led Skin Camouflage Clinic. *Nurs Stand*
50 2006;20(24):74, 6, 8 passim doi:10.7748/ns.20.24.74.s59 [published February 2006].
51
52
53
54 18 Walker T, Shaw J, Ranote S, et al. Medical Skin Camouflage: A Recovery Intervention for Female
55 Prisoners who Self-Harm? *Crim Behav Ment Health* 2014;24(5):317-20 doi:10.1002/cbm.1943
56 [published 03 November 2014].
57
58
59
60

- 1
2
3 19 Kenning C, Cooper J, Short V, et al. Prison staff and women prisoner's views on self-harm; their
4 implications for service delivery and development: A qualitative study. *Crim Behav Ment Health*
5 2010;20(4):274-84 doi:10.1002/cbm.777 [published online 05 July 2010].
6
7
8
9
10 20 Ranote S. Skin camouflage service: A first for mental health; Innovation to implementation. Talk
11 presented at Self-harm in Women's Prisons Conference; 2016; University of Manchester.
12
13
14
15 21 Changing Faces. Skin Camouflage Practitioner Training Trainer's Practical Course Manual for
16 COVER Project. London, England: Changing Faces, 2015.
17
18
19
20 22 Walker T, Shaw J, Turpin C, et al. The WORSHIP II study: a pilot of psychodynamic
21 interpersonaltherapy with women offenders who self-harm. *J Forens Psychiatry Psychol*
22 2017;28(2):158-71 doi:10.1080/14789949.2017.1301529 [published online 08 March 2017].
23
24
25
26
27 23 Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for
28 routine clinical use. *Clin Exp Dermatol* 1994;19:210-6 doi:10.1111/j.1365-2230.1994.tb01167.x
29 [published May 1994].
30
31
32
33 24 Rosenberg M. Society and the adolescent self-image. Princeton, N.J: Princeton University Press;
34 1965.
35
36
37
38
39 25 Gratz KL. Measurement of Deliberate Self-Harm: Preliminary Data on the Deliberate Self-Harm
40 Inventory. *J Psychopathol Behav Assess* 2001;23(4):253-63 doi: 10.1023/A:1012779403943
41 [published December 2001].
42
43
44
45 26 Zanarini MC. Zanarini Rating Scale For Borderline Personality Disorder (ZAN-BPD): A
46 Continuous Measure of DSM-IV Borderline Psychopathology. *J Pers Disord* 2003;17(3):233-242 doi:
47 10.1521/pedi.17.3.233.22147 [published July 2003].
48
49
50
51 27 Tennant R, Hiller L, Fishwick R, et al. The Warwick-Edinburgh Mental Well-being Scale
52 (WEMWBS): development and UK validation. *Health Qual Life Outcomes* 2007;5(63)
53 doi:10.1186/1477-7525-5-63 [published 27 November 2007].
54
55
56
57
58 28 Beck AT, Kovacs M, Weissman A. Assessment of Suicidal Intention - Scale for Suicide Ideation. *J*
59 *Consult Clin Psych* 1979;47(2):343-52 doi:10.1037/0022-006X.47.2.343[published April 1979].
60

1
2
3
4
5 29 Beck AT, Steer RA, Brown GK. Manual for the BDI-II. San Antonio: TX: Psychological
6 Corporation; 1996.
7

8
9
10 30 Wang YP, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: a
11 comprehensive review. *Rev Bras Psiquiatr* 2013;35:416-31 doi:10.1590/1516-4446-2012-1048
12 [published online 23 December 2013].
13
14

15
16
17 31 Beck AT, Weissman A, Lester D, et al. The Measurement of Pessimism: The Hopelessness Scale.
18 *J Consult Clin Psych* 1974;42(6):861-5 doi:10.1037/h0037562 [published December 1974].
19

20
21
22 32 Boduszek D, Shevlin M, Mallett J, et al. Dimensionality and construct validity of the Rosenberg
23 Self-Esteem Scale within a sample of recidivistic prisoners. *J Crim Psychol* 2012;2(1):19-25 doi:
24 10.1108/20093821211210468.
25

26
27
28 33 Gusi N, Olivares PR, Rajendram R. The EQ-5D Health-Related Quality of Life Questionnaire.
29 Springer. USA, New York. 2010:87-99.
30

31
32
33 34 Haywood KL, Garratt AM, Dziedzic K, et al. Generic measures of health-related quality of life in
34 ankylosing spondylitis: reliability, validity and responsiveness. *Rheumatology* 2002;41:1380-87 doi:
35 10.1093/rheumatology/41.12.1380 [published 01 December 2002].
36
37

38
39
40 35 Ware JJ, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and
41 preliminary tests of reliability and validity. *Med Care* 1996;34(3):220-33 doi:10.2307/3766749
42 [published April 1996].
43
44

45
46
47 36 Barrett B, Byford S. Collecting service use data for economic evaluation in DSPD populations:
48 development of the Secure Facilities Service Use Schedule. *Br J Psychiatry* 2007;190(suppl. 49):s79-
49 s79 doi:10.1192/bjp.190.5.s75 [published online 03 January 2018].
50

51
52
53 37 Braun V, Clark V. Using Thematic Analysis in Psychology. *Qual Res Psychol* 2006;3(2):77-101
54 doi:10.1191/1478088706qp063oa [published online 21 July 2008].
55
56

57
58
59 38 Boyatzis R. Transforming Qualitative Information: Thematic Analysis and Code Development.
60 California: Sage 1998.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

37. Munn K, Godwin E, Koola J, et al. Qualitative research: Rigour and quality in research. *BMJ* 2015; 351:169-72
doi:10.1136/bmj.g4541

For peer review only




Figure 1. Consort diagram.

239x310mm (600 x 600 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description
Administrative information		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry
	2b	All items from the World Health Organization Trial Registration Data Set
Protocol version	3	Date and version identifier
Funding	4	Sources and types of financial, material, and other support
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors
	5b	Name and contact information for the trial sponsor
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
Introduction		
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
	6b	Explanation for choice of comparators
Objectives	7	Specific objectives or hypotheses
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions
---------------------	-----	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

1			
2	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central
3	concealment		telephone; sequentially numbered, opaque, sealed envelopes),
4	mechanism		describing any steps to conceal the sequence until interventions are
5			assigned
6			
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,
8			and who will assign participants to interventions
9			
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial
11	(masking)		participants, care providers, outcome assessors, data analysts), and
12			how
13			
14		17b	If blinded, circumstances under which unblinding is permissible, and
15			procedure for revealing a participant's allocated intervention during
16			the trial
17			

18 **Methods: Data collection, management, and analysis**

19			
20	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other
21	methods		trial data, including any related processes to promote data quality (eg,
22			duplicate measurements, training of assessors) and a description of
23			study instruments (eg, questionnaires, laboratory tests) along with
24			their reliability and validity, if known. Reference to where data
25			collection forms can be found, if not in the protocol
26			
27			
28		18b	Plans to promote participant retention and complete follow-up,
29			including list of any outcome data to be collected for participants who
30			discontinue or deviate from intervention protocols
31			
32	Data	19	Plans for data entry, coding, security, and storage, including any
33	management		related processes to promote data quality (eg, double data entry;
34			range checks for data values). Reference to where details of data
35			management procedures can be found, if not in the protocol
36			
37	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.
38	methods		Reference to where other details of the statistical analysis plan can be
39			found, if not in the protocol
40			
41			
42		20b	Methods for any additional analyses (eg, subgroup and adjusted
43			analyses)
44			
45		20c	Definition of analysis population relating to protocol non-adherence
46			(eg, as randomised analysis), and any statistical methods to handle
47			missing data (eg, multiple imputation)
48			

49 **Methods: Monitoring**

50			
51	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role
52			and reporting structure; statement of whether it is independent from
53			the sponsor and competing interests; and reference to where further
54			details about its charter can be found, if not in the protocol.
55			Alternatively, an explanation of why a DMC is not needed
56			
57			
58			
59			
60			

1		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial
2			
3			
4			
5			
6	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct
7			
8			
9			
10	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor
11			
12			
13			

14 Ethics and dissemination

15			
16	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval
17			
18			
19	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)
20			
21			
22			
23			
24	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)
25			
26			
27		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable
28			
29			
30	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial
31			
32			
33			
34			
35	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site
36			
37			
38	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators
39			
40			
41			
42	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation
43			
44			
45	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions
46			
47			
48			
49			
50		31b	Authorship eligibility guidelines and any intended use of professional writers
51			
52			
53		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code
54			
55			
56			
57			
58			
59			
60			

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.